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ABSTRACT 
 
Background: Females with cystic fibrosis have higher mortality rates than their 
male counterparts. Pulmonary function defined as forced expiratory volume in 1 
s (FEV1) is a predictor of mortality. However, when pulmonary function is 
accounted for, females still have a higher mortality rate than males. Independent 
of lung function, peak oxygen uptake (V̇O2peak) is a significant predictor of 
mortality, with higher values of V̇O2peak relating to a lower risk of mortality. In 
healthy children, V̇O2peak is significantly different between sexes, however it has 
yet to be determined whether sex differences in V̇O2peak occur in CF. Aim: To 
identify sex differences in exercise capacity in young people with CF, when 
appropriately scaled for different body size variables and adjusted for key clinical 
parameters such as lung function and nutritional and maturity status. Methods: 
52 young people (29 males and 23 females) aged 8 – 25 y with CF underwent a 
ramp cycle test to exhaustion. 47 completed an additional supramaximal cycle 
test to exhaustion at 110 % of ramp test peak power to verify that a true V̇O2max 
was obtained. V̇O2peak was scaled allometrically and using the ratio standard 
method. ANCOVAs were utilised to remove the influence of clinical parameters. 
Results: V̇O2peak was significantly lower in females than males for absolute V̇O2peak (p < 0.001, 1.41 ± 0.38 L∙min-1 and 2.17 ± 0.82 L∙min-1, respectively), V̇O2peak/BM*β (p < 0.001, 53.28 ± 10.93 mL·kg*0.82·min-1 and 73.04 ± 19.57 
mL·kg*0.82·min-1, respectively), V̇O2peak/BSA*β (p < 0.001, 814.58 ± 159.05 
mL·m2(*1.29)·min-1 and 1108.06 ± 296.24 mL·m2(*1.29)·min-1, respectively), and V̇O2peak/Stature*β  (p < 0.001, 464.76 ± 86.69 mL·m*2.42·min-1 and 627.77 ± 183.28 
mL·m*2.42·min-1, respectively). These remained significant with the inclusion of co-
variates, peak height velocity (PHV), age, body mass index (BMI) and FEV1. 
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Conclusions: Irrespective of the scaling method and body size variable used or 
if adjusted for key clinical parameters (age, PHV, BMI and FEV1), young females 
with CF have a reduced V̇O2peak compared to males. Future studies should 
consider sex differences in exercise capacity as a potential contributor to 
differences in mortality. 
 
Keywords: respiratory disease, exercise capacity, children, adolescents, 
cardiopulmonary exercise testing.  
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1. INTRODUCTION 
Cystic Fibrosis (CF) is a complex, multi-organ, life shortening disease caused by 
a mutation in the CF transmembrane conductor regulator (CFTR) protein. The 
disease primarily effects the lungs and digestive system, however the mutated 
CFTR protein is expressed in the membranes of cells lining the skin and 
reproductive tracts as well. One in 25 people in the UK are carriers of the 
recessive gene (~ two million people) leading to 1 in 2,500 babies born with CF 
in the Caucasian population.  
Females with CF have been found to have higher rates of mortality than males 
with CF. Rosenfeld et al., (1997) used CF registry data in the US from 1988-1992 
and reported females below 20 y to have a 60 % greater risk of death than males 
below 20 y. Interestingly, the sex difference became less significant with 
increasing age (Rosenfeld et al., 1997), contradicting previous theories that 
hormonal differences may be the cause of greater mortality rates in females 
(Gurwitz et al., 1979). Some studies dispute the sex gap entirely, arguing that 
improved diagnosis and therapies, especially lung airway clearance treatments, 
have narrowed the sex gap in mortality (Viviani et al., 2011; Verma et al., 2005). 
However, according to the Cystic Fibrosis Trust registry (2017), median predicted 
survival age for men and women is still significantly different (47.9 y and 44.2 y 
respectively). This suggests, despite improved therapies, females are still at a 
higher risk of early mortality than their male counterparts. 
Due to the nature of CF, parameters of lung function have been considered the 
best predictors of mortality, specifically forced expiratory volume in 1 s (FEV1) 
and FEV1%predicted. Those with < 30 % FEV1%predicted have a 50 % chance of 
mortality in two years compared to a less than 5 % chance in those with > 60 % 
FEV1%predicted (Kerem et al., 1992). Furthermore, Kerem et al., (1992) reported risk 
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of death with an FEV1%predicted of 20-30 % to be 18 % higher in females than males 
with CF, concluding that females with CF have a less favourable mortality for a 
given FEV1. This conclusion was supported by Corey et al., (1997), who have 
shown steeper declines of FEV1%predicted in females with CF than males with CF. 
Despite this, FEV1%predicted only partially accounts for reduced mortality, with 
females experiencing a ~60 % greater mortality than males when pulmonary 
function is removed as an explanatory factor (Rosenfeld et al., 1997).  
The National Health Service (NHS) in the UK provides vital support, treatment 
and management for all those with CF, utilising lung function tests to assess the 
individual. Each year a patient will undergo an annual review of overall health to 
track progression, which enables continual improvement and individualisation of 
treatment. All data from annual review is added to the UK CF Trust registry, 
creating a national database. Treatments include medicines, physiotherapy, 
nutrition, surgery and exercise. Investigations into exercise in CF started in the 
1970s and exercise testing in cardiology was introduced in 1980s. Since then, 
exercise testing in clinical populations has significantly increased, however it is 
still described as a specialised test in many CF NHS clinics. In the last few 
decades exercise initiatives, such as ‘Exercise is Medicine’ launched in 2007 
(Lobelo et al., 2014), have been developed to encourage health care 
professionals to utilise physical activity (PA) as a treatment and ‘prescribe’ 
exercise with continual, routine testing.  
Independent of lung function, exercise capacity (expressed through V̇O2peak [peak 
oxygen uptake]1), has been shown to be a significant predictor of mortality in CF 
 
 
1 V̇O2max is the oxygen intake during an exercise intensity at which actual oxygen intake reaches a 
maximum, eliciting a plateau. V̇O2peak is the highest V̇O2 attained in a specific test and regardless of the 
subject’s effort (Whipp, 2019) and may not elicit a plateau. 
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(Radtke et al., 2017; Pianosi et al., 2005; Nixon et al., 1992). A higher value of V̇O2peak relates to lower mortality rates. Only ~30 % of the reduced exercise 
capacity elicited in CF is explained by pulmonary function (Pastre et al., 2014) 
indicating there are other factors involved. Few studies have explored sex 
differences in regards to exercise capacity in CF. Kilbride et al., (2012) reported 
no significant differences in V̇O2peak when scaled for body mass between males 
and females with CF (46.7 mL·kg-1·min-1 and 41.9 mL·kg-1·min-1, respectively). 
Conversely, Gruber et al., (2011) identified a significant difference between males 
and females V̇O2peak, in absolute and relative terms (32.1 mL·kg-1·min-1 and 29.5 
mL·kg-1·min-1, respectively), however there is a large difference in sample size 
between the Kilbride and Gruber studies (16 and 344 respectively) which is likely 
to have caused the differences in significance. Ratio standard scaling is 
reportedly unsuitable in healthy children, and previous literature in one CF centre 
reports a broad range of body sizes and compositions (Hanna and Weiner, 2015), 
raising the question whether scaling for body mass is a sufficient scaling 
approach in CF. Scaling is especially prominent when assessing differences in 
the paediatric population due to the influences of puberty on growth and body 
composition. In healthy children, it has been reported that V̇O2peak normalised for 
fat free mass (FFM) or muscle mass (MM) elicits a ~5 % and ~1 % lower V̇O2peak 
in females respectively (Welsman et al., 1997). It may be that a similar 
phenomenon is seen in the CF paediatric population. In many of these studies, 
the authors have only accounted for the influence of body mass to assess sex 
differences in the V̇O2peak response; they failed to account for other clinical factors 
that could influence results such as genotype, nutritional (Vieni et al., 2013; 
Fogarty et al., 2012) and maturity status.  
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Therefore, the purpose of the present thesis is to identify sex differences in 
exercise capacity in young people with CF, when appropriately scaled for different 
body size variables and adjusted for key clinical parameters such as lung 
function, age and nutritional status. 
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2. LITERATURE REVIEW 
2.1 Cystic fibrosis pathophysiology  
CF is an autosomal recessive life shortening disease, primarily targeting the lungs 
and digestive system. It is the most common genetic disease in the Caucasian 
population with a prevalence of 1 in 2,500 babies born equating to ~10,400 
people in the UK, 53.2 % of which are male (Cystic Fibrosis Trust, 2017c). One 
in 25 people are carriers of the defective recessive gene (over two million people 
in the UK), if two carriers have a child there is a 25 % chance they will be born 
with CF (Fig. 2.1). A median projected life expectancy for a new-born with CF is 
~47 years of age in the UK (Cystic Fibrosis Trust, 2017a). In 2013, the median 
age of death was only 29 years showing the magnitude of development in care 
and treatment for people living with CF over the last 5 years alone (Cystic Fibrosis 
Trust, 2016). It is understood that females with CF have a lower life expectancy, 
living ~3.7 years less than males (Cystic Fibrosis Trust 2017c).  
 
 
 
 
 
 
 
Figure 2.1. The probability of two carrier parents producing a child with CF. 
(Cystic Fibrosis Trust, 2015b). 
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The CFTR gene, located on chromosome 7 (Kerem et al., 1989), codes for the 
cyclic adenosine monophosphate (cAMP) - dependent CFTR protein found in 
epithelial cells that produce mucus, sweat, saliva and digestive enzymes that line 
most exocrine organs such as the lungs/airways, pancreas and liver (Thomson 
and Harris, 2008). Healthy CFTR proteins behave as channels for negatively 
charged chloride ions (Cl-) moving in and out of cells. Creating a high 
concentration of solute on one side of the membrane causes water to move from 
low to high concentrations via osmosis, equalising the gradient. CF is a result of 
a defective CFTR gene that causes mutation or dysfunction of the CFTR protein 
(Tucker et al., 2017). In a person with CF, the movement of Cl- is dysregulated 
causing increased sodium (Na+) and water retention inside the cell, resulting in 
thickening of the viscous mucus layer.   
There are varying severities of CF due to over 1,700 different mutations of the 
CFTR gene, which can be classified (class I-VI; Table 2.1 and Fig. 2.2) by how 
they impact the production, processing, conduction, transportation or volume of 
the CFTR protein (Cystic Fibrosis Foundation, 2017a). Class I mutations result in 
no synthesis of a functional CFTR protein and class VI causes accelerated 
turnover or decreased stability of the CFTR protein at the cell membrane. Of 
people with CF in the UK, 90 % have at least one allele with the Phe508del class 
II mutation (Cystic Fibrosis Trust, 2015a), which causes degradation of the 
protein shortly after synthesis. Consequently, the protein does not reach the 
surface of the cell membrane (Rowe, Miller and Sorscher, 2005) and cannot carry 
out its function. 
21 
 
 
 
 
 
 
 
 
Figure 2.2. Classes of defects in the CFTR gene. No synthesis (class I); defective 
protein maturation and premature degradation (class II); defective or disordered 
channel regulation (class III); defective or disordered chloride or channel 
conductance (class IV); reduced synthesis of CFTR protein (V); decreased 
stability or increased turnover of CFTR from the cell surface (VI). (Reproduced 
from Rowe, Miller and Sorscher, 2005). 
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Table 2.1. Classes of CFTR mutation and defect, with examples of specific 
mutations. (Boyle and De Boeck, 2013). 
CFTR; Cystic fibrosis transmembrane conductance regulator. 
 
These mutations ultimately lead to many complications and symptoms in CF, of 
which, the lungs and airways are largely affected. The cilia on CF cells are smaller 
and flatter so therefore cannot beat away the thickened mucus layer, causing 
ineffective clearance of bacteria from the lungs (Thomson and Harris, 2008; Fig. 
2.3). This leaves people with CF prone to infection, with 25 % of the paediatric 
population in 2017 developing influenza (Cystic Fibrosis Trust, 2018f), which can 
Class Defect Examples 
I No functional CFTR 
protein 
Gly542X 
Trp1282X 
Arg553X 
621+1G→T 
II Defective CFTR 
maturation 
PHE508del 
Asn1303Lys 
Ile507del 
Arg560Thr 
III Defective channel 
regulation 
Gly551Asp 
Gly178Arg 
Gly551Ser 
Ser549Asn 
IV Defective channel 
conductance 
Arg117His 
Arg347Pro 
Arg117Cys 
Arg334Trp 
V Reduced CFTR 
synthesis 
3849+10kbC→T 
2789+5G→A 
3120+1G→A 
5T 
VI Increased turnover of CFTR from the cell 
surface 
4326delTC 
Gln1412X 
4279insA 
23 
often lead to inflammation caused by trapped bacteria resulting in damage to the 
airway lining. Gradually, continual reinfection will lead to a progressive decline in 
pulmonary function, the extent to which this occurs is dependent upon the 
individual. Females tend to experience a greater decline (Cystic Fibrosis Trust, 
2018f).  
Figure 2.3. CFTR protein in the airways of a healthy and CF cell. (Thomson 
and Harris, 2008). 
 
A further complication of CF is an increased reserve volume to total lung capacity 
ratio (hyperinflation). This occurs due to a reduced ability to expire, causing 
people with CF to work harder than average for a reduced amount of O2 than 
those without CF. Due to viral infections, wheezing can be experienced, and 
some people with CF may develop asthma as a result of narrowing and damage 
to airways. Other complications include; haemoptysis caused by ruptures in small 
blood vessels often associated with infection; Pneumothorax and nasal polyps 
(outgrowths of the mucus membranes as a response to irritation or inflammation).  
The leading cause of death in CF is deterioration and failure of the pulmonary 
system (Flume et al., 2009), therefore management of lung health is the primary 
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target of treatment. The most common way to assess lung function in children 
and adults with CF is by spirometry, which measures FEV1 and forced vital 
capacity (FVC) (Fig. 2.4). A value of 85 % predicted FEV1 is the threshold of near 
normal lung health and is often classified as mild CF (Cystic Fibrosis Trust, 2015). 
 
Figure 2.4. Lung Volumes. FVC = Forced vital capacity; FEF25-75 = Forced 
expiratory flow from 25-75 % of vital capacity; FEV1 = Forced expiratory volume 
in 1 second. (Metro Health, 2018). 
 
Dysregulation of ions and lack of osmotic drive also affects cells in the pancreas 
and digestive system. The small channels in the pancreas can become blocked, 
due to viscous secretions reducing the volume of pancreatic enzymes that reach 
the small intestine and causing pancreatic insufficiency. However, humans have 
a large reserve of pancreatic enzymes such that we only require 10 % for normal 
functioning (Thomson and Harris, 2008), therefore ~10-15 % of people with CF 
can be pancreatic sufficient (Borowitz et al., 2004). Importantly, these individuals 
do not have normal pancreatic function and may become pancreatic insufficient 
with time or severity of the disease. In these pancreatic sufficient individuals, 
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some of the cells in the pancreas die, leading to inflammation and sometimes 
pancreatitis. Those with pancreatic insufficiency cannot get pancreatitis as all of 
the cells die and become fibrotic tissue. 
Meconium ileus is a form of bowel obstruction common in the CF new-born 
population, 90 % of new-borns with meconium ileus are diagnosed with CF 
(Southampton Children’s Hospital, 2016). This is due to decreased intestinal fluid 
secretion, which makes the meconium (bowel contents) thicker and stickier. 
Thus, meconium is harder to move through the bowel and often gets stuck at the 
ileocecal junction (between the small and large intestine) making it difficult for 
individuals with CF to defecate. Distal intestinal obstruction syndrome, gastro-
oesophageal reflux and rectal prolapse are other examples of altered digestive 
function in CF, further descriptions can be found in Thompson and Harris (2008). 
About 40 % of the CF population have liver irregularities, however only 5-10 % 
experience problems and symptoms (Cystic Fibrosis Trust, 2017b). Intrahepatic 
bile ducts (transport bile salts from the liver and gallbladder to the duodenum) 
can become irritated and blocked by thick mucoid secretions (Lamireau et al., 
2006) sometimes called gallstones. Eventually liver cirrhosis, a late and severe 
stage of scarring, can occur causing irreversible damage to the liver (Cystic 
Fibrosis Trust, 2017b). Scarring causes increasing back pressure of blood flow 
and enlargement of the spleen and blood vessels, termed portal hypertension.  
CF related diabetes mellitus (CFRDM) is present in approximately 2 % of children 
and 19 % of adolescents in the CF population. There is contrasting evidence 
relating to differences in sex, with some literature suggesting a ~5 % higher 
incidence in females compared to than males, when averaged over an age range 
of 13 to > 35 years (Marshall et al., 2005). In contrast, Moran et al., (2009) 
reported no sex differences in CFRDM prevalence overall, but found a higher 
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incidence in females aged 30-39 y. Such contradictory findings may therefore be 
attributed to using differing age categories. CFRDM occurs due to the scarring of 
the pancreas. Thus, CFRDM is normally a gradual process starting with the 
inability to produce sufficient insulin to deal with the demands of large quantities 
of glucose. In turn, the blood glucose levels remain high for longer periods of time 
meaning more insulin is needed but not enough is being produced, resulting in 
glucose intolerance. Furthermore, those with CFRDM may not be able to utilise 
insulin in the correct way, like those with type 2 diabetes (Cystic Fibrosis 
Foundation, 2017b). However, as some native insulin is produced, CFRDM is 
often mild in comparison to other non-CF related diabetes.  
Many adults with CF struggle to synthesise a healthy amount of new bone for 
their age, and therefore develop low bone mineral density (BMD), consequently 
increasing bone fragility and leaving bones prone to fracture. Healthy people 
reach peak bone mass shortly after adolescence (> 20 y), of which, in the two-
year period only 25% of total skeletal mass is obtained (Smitt and Mehls, 2008), 
therefore the years prior to peak bone mass (i.e. adolescence) may be crucial in 
development. Conway et al., (2000) reported as many as 79 % of males and 59 
% of females with CF to have osteoporosis or osteopenia in at least one site.  It 
is unclear whether the dysfunctional CFTR gene is directly responsible for low 
BMD, however, many studies have shown an association between low BMD and 
disease severity (Cystic Fibrosis Trust, 2007; Buntain et al., 2004; Haworth et al, 
2002; Conway et al., 2000). Furthermore, people with CF have poor nutrition and 
digestion/absorption of what they do ingest. Abnormal absorption of fat-soluble 
vitamins and vitamin D deficiency due to reduced exposure to the sun can lead 
to osteomalacia or rickets (Cystic Fibrosis Trust, 2007). Lack of key nutrients such 
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as vitamin D, K and calcium also contribute to the poorer bone health experienced 
in CF.  
Excessive Na+, Cl- and potassium (K+) loss is often experienced in CF, largely 
through sweating but also vomiting (Thomson and Harris, 2008) and diarrhoea 
(Gutierrez et al., 2016). In non-CF individuals, Cl- and Na+ are reabsorbed 
through CFTR channel proteins, however in CF these channels are dysfunctional, 
therefore reabsorption cannot occur (Gutierrez et al., 2016). Furthermore, under 
normal conditions an increase in extracellular osmolality is a trigger for thirst, 
however this trigger is reduced in people with CF increasing risk of dehydration. 
The combination of these two factors makes CF patients more susceptible to 
dehydration than healthy individuals. The kidneys can sometimes try to 
compensate by releasing other electrolytes, leaving people with CF feeling 
lethargic, especially infants and children (Thomson and Harris, 2008). CF can 
also cause many other complications such as gall bladder disease, urinary 
incontinence, infertility, arthritis and more. Thus, CF is much more commonly 
regarded as a multi–organ disease.  
2.2 Treatment   
CF centres provide care from a multidisciplinary team of specialists to deliver 
treatment of CF. Medicines can be used to treat different symptoms of CF 
disease. Medicine, for treatment of the lungs, can be taken three ways; orally, 
through intravenous methods and/or by inhaling through a nebuliser (Cystic 
Fibrosis Trust, 2018a), although intravenous methods are typically only used if 
oral treatment is ineffective. Bronchodilator drugs and steroids, such as 
corticosteroids or glucocorticoids, are inhaled into the lungs to relax the muscles 
in the airways, which relieves tightness and makes breathing easier. This can 
also aid the effectiveness of other medication as air can move more freely through 
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the pulmonary system. Often working for ~4-6 hours, bronchodilators take 20 
minutes to take effect and may have some side effects such as nausea and 
dizziness (Cystic Fibrosis Foundation, 2018). Mucolytic enzymes can 
complement bronchodilators as they break down mucus, widening the lumen of 
the airways and easing clearance from the lungs. Antibiotics are another key 
medication that treat against bacterial infections in the lungs by inhibiting growth 
or killing bacteria. Guidance from the Cystic Fibrosis Trust suggests all new-borns 
diagnosed with CF be placed on anti-staphylococcal antibiotic prophylaxis with 
flucloxacillin for 3 y. Some patients, such as those deteriorating on normal 
therapies, can be placed on trials of antibiotics with the aim of slowing pulmonary 
function decline (Cystic Fibrosis Trust, 2009). Bisphosphonates and the steroid 
Flixonase can be used to treat other CF related complications such as low BMD 
and rhinitis (swelling in the nasal airways) respectively (Cystic Fibrosis Trust, 
2018a). 
Energy needs of people with CF can reach 150-200 % of normal requirements, 
especially when fighting infections (Cystic Fibrosis Trust, 2018b). Therefore, 
treatment is in place to aid digestion and absorption of food. Enzyme capsules 
can be used to assist breakdown of food in the digestive system, however much 
of this treatment is highly individualised due to age, stature, weight, lung function 
and PA differences. Energy drinks and other high energy foods can be used to 
counter unsuccessful digestion, but those with CFRDM have to carefully balance 
their energy intake with insulin treatments, making it more challenging to meet 
energy requirements. In most part, hospitals and clinics provide specialist 
dieticians to aid effective energy balance for those with and without CFRDM.  
Physiotherapy is largely used in CF to effectively loosen and clear mucus build 
up in the lungs, however it can aid with other problems that may add to the strain 
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of the disease such as back and continence issues (Cystic Fibrosis Trust, 2018c). 
Autogenic drainage is a technique that uses a series of sighs and breaths to move 
the mucus from the smaller airways into larger ones, requiring the patient to feel 
and control the mucus in order to cough and clear it at the optimum point. There 
are many other techniques to remove mucus (including use of devices to aid 
removal) and physiotherapy to remove it can be uncomfortable. Therefore, 
physiotherapists often choose a technique based on what works best with the 
individual with sessions lasting anywhere between 10 – 60 min. Physiotherapists 
aim to create a programme of techniques that allow patients to independently 
carry out treatment, allowing them more freedom as they grow into adulthood.  
Organ transplants can be considered when all previous treatments no longer 
have any impact, and are undertaken when organs, such as lungs or liver, are 
severely impaired, causing the patient to become unwell, and in turn requiring 
additional care. Kerem et al., (1992) stated that females, due to their greater risk 
of mortality for a given FEV1, may need to be considered for a lung transplant 
earlier than their male counterparts. Before a transplant operation can ensue, the 
patient with CF must first be assessed and wait for the organ to become available, 
which may take some time. On average a person with CF will wait 18 months for 
an organ and only 2 in 3 people on the organ list will receive a transplant (Cystic 
Fibrosis Trust, 2018d). A lung transplant can significantly improve quality of life 
for a person with CF, however they will unfortunately not have the life expectancy 
of a healthy individual and will require continual treatment for the rest of the body. 
Of patients who have undergone a lung transplant, 50 % will live at least 5 y after 
the operation (Cystic Fibrosis Trust, 2018d).  
Arguably the least invasive and most ‘normal’ form of treatment is exercise. Any 
planned and structured activity requiring physical exertion that is carried out to 
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improve health and fitness is termed exercise; whereas PA is defined as bodily 
movement, produced by the skeletal muscles, requiring energy expenditure 
above rest (Caspersen et al., 1985). Swimming, running, football and other sports 
are all examples of exercise suitable for CF treatment. Using a trampoline is good 
choice of exercise in children as it is typically seen as enjoyable, however the risk 
of injury to benefits is often disputed (Barak et al., 2005). Selvadurai et al., (2002) 
reported a 2 % and 6 % greater increase in FEV1 %predicted with aerobic and 
anaerobic training programmes, respectively, compared with standard chest 
physiotherapy only. Not only does exercise enhance mucus clearance 
(McIlwaine, 2007), but it is further useful to increase MM and physical fitness 
(Cystic Fibrosis Trust, 2018e; Radtke, et al., 2017).  
2.3 Exercise testing in cystic fibrosis 
Standard spirometry tests only allow assessment of the lung function, but not the 
stress that exercise or PA puts on the pulmonary, cardiovascular and muscular 
systems (Ferrazza et al., 2009). Therefore, tests have been developed to assess 
the complex interaction of the body’s systems during exercise. In some cases, 
field tests are used to assess exercise capacity in CF. Although they require less 
expensive equipment, field tests tend to use more space and do not provide gas 
exchange data, which can be useful as it provides quantitative values of key 
exercise parameters. The six-minute walk test (6MWT) is self-paced and 
submaximal in all but those with severe CF (Hebestreit et al., 2015). Whereas, 
incremental shuttle tests such as the 3 min step test, 20 m shuttle test and 10 m 
shuttle test, are all externally paced with multiple levels designed to assess 
exercise capacity. Field tests cannot directly measure V̇O2peak, however they can 
be useful in a clinical environment to assess children for lung transplants or 
following transplants where exercise capacity is limited (Hebestreit et al., 2015). 
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The steep ramp test (SRT) is performed on a cycle ergometer and estimates V̇O2peak from peak work rate using a validated algorithm (Bongers et al., 2013). 
Initially, participants undertake a warm-up at 25 W before the resistance 
increases by 10, 15 or 20 W∙10 s-1 depending on the stature of the participant 
(<125 cm, 125-150 cm and >150 cm respectively). Cadence is kept between 60-
80 rev∙min-1, and maximal exercise is accepted when cadence falls below 60 
rev.min-1 and participants show subjective signs of intense effort (Bongers et al., 
2015). Bongers and colleagues found that the SRT over reported work rate (WR) 
in both absolute and relative terms when compared to a cardiopulmonary 
exercise test (CPET) but under reported peak heart rate (HRpeak). However, peak 
WR (WRpeak) attained during SRT correlates strongly (r = 0.82) with V̇O2peak 
attained during a CPET, which could show that the SRT can be used to 
predict	V̇O2peak in CF and may be less demanding as suggested by the ~8 % lower 
HRpeak reported by Bongers et al., (2015). However, rating of perceived exertion 
(RPE) was not reported in the above study by Bongers, therefore, perceptually 
the SRT may be more or equally demanding on the participant. 
Laboratory tests such as the Bruce treadmill protocol have been developed to 
directly assess measures of fitness. Originally the Bruce protocol was used to 
assess aerobic impairment in cardiovascular disease but has since been 
expanded for use in CF and other pulmonary diseases such as Chronic 
Obstructive Pulmonary Disease (COPD; Hebestreit et al., 2015). The protocol is 
a continuous, incremental treadmill test consisting of 3 min stages at a specified 
gradient and speed (1 = 10 % grade, 2.7 km∙h-1; 2 = 12 %, 4 km∙h-1; 3 = 14 %, 
5.4 km∙h-1; 4 = 16 %, 6.7 km∙h-1; 5 = 18 %, 8.0 km∙h-1, 6 = 20 %, 8.8 km∙h-1; 7 = 
22 %, 9.6 km∙h-1). Some CF patients who have an expected lower exercise 
capacity can use the modified Bruce Protocol, which has two additional stages 
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prior to stage 1. These stages are at the same speed as stage 1 but at a lower 
percent grade (stage 0 = 0 %; stage ½ = 5 %). Outcome variables measured 
included V̇O2peak and exercise time; WRpeak can be calculated by using final 
percent grade, speed, time at final stage, body mass and gravity. Despite being 
a valid and reliable exercise test in both healthy children/ adults and in CF 
populations (Hebestreit et al., 2015), determining WRpeak and V̇O2peak on a 
treadmill is less precise than with cycle ergometers (e.g. Godfrey Protocol) as 
these parameters are often calculated from test parameters such as exercise 
time. Test-retest reliability of V̇O2peak is r = 0.94 in healthy children and r = ~0.86 
in healthy adults (Hebestreit et al., 2015). Furthermore, the authors failed to report 
test-retest reliability for CF populations. 
The Godfrey protocol has been used in CF with varying degrees of severity, 
cardiopulmonary impairment and age. The test is a stature dependent, 
continuous, incremental cycle test to volitional fatigue. Starting at 10 W (stature 
< 120 cm), 15 W (stature 120-150 cm) and 20 W (stature >150 cm) the 
electronically braked cycle ergometer holds the power output constant regardless 
of cadence; however participants are encouraged to maintain a constant cadence 
throughout. WR increases every minute and outcome measures of V̇O2, SPO2 
and HR are recorded during the last 15 s of each increment. Those with mild or 
moderate CF can follow this original protocol. However, in severe CF a modified 
protocol can be recommended using smaller increments i.e. 10 W for FEV1 < 30 
% (Hebestreit et al., 2015). The Godfrey protocol at increments of 15 W∙min-1 has 
been shown to be very reproducible over 28 days in adults with CF, but not 
children with CF, with test retest variations of 6 % WRpeak and 6.9 % in V̇O2max 
(McKone et al., 1999). This protocol has been used to determine V̇O2peak, which 
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has a prognostic value of equal importance to lung function parameters, 
specifically FEV1 (Nixon et al., 1992).  
CPETs such as the Godfrey and Bruce protocols are the gold standard to assess 
exercise capacity, as they can assess gas exchange measures, the primary 
outcome of which is V̇O2max. However not all CF patients are able to complete a 
maximal exercise test, therefore some authors have suggested the use of 
submaximal measures as an alternative assessment of exercise capacity 
(Williams et al., 2014). The gas exchange threshold (GET) has been proposed 
as a non-invasive estimation of the lactate threshold that demarcates moderate 
and heavy intensity exercise domains. However, the GET can be difficult to detect 
in chronic respiratory conditions; COPD non-detection is ~40 % (Sue et al., 1988), 
whereas CF (when 80 % of participants were mild-moderate disease cases) had 
a reported 15 % non-detection (Thin et al., 2002). Gruet et al., (2010) concluded 
that the oxygen uptake efficiency slope (OUES), which describes the relationship 
between V̇O2 and minute ventilation (V̇&), is a more useful submaximal parameter 
than the GET. The OUES was developed in 1996 by Baba and colleagues and, 
despite being shown to be reliable in adults with CF (Gruet et al., 2010), Williams 
et al., (2018) have concluded the OUES is not a valid alternative to maximal 
measures of aerobic fitness in children and adolescents with CF. However, the 
above study by Gruet et al., (2010) had a more biased population favouring males 
compared to Williams et al., (2018), which may have influenced the significance 
of results as sex is reportedly a determinant of OUES (Buys et al., 2015). In 
addition, Marinov et al., (2007) suggested that healthy boys have significantly 
higher values of OUES than girls.  
Irrespective of whether healthy, CF or other disease status, exercise testing does 
not always elicit a plateau (the primary criteria for V̇O2max; Barker et al., 2011) in 
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the majority of children, leading to the term V̇O2peak being more commonly used 
when referring to exercise capacity in children. With V̇O2max, secondary criteria 
are often used to determine whether true max has been attained (e.g. heart rate 
(HR) ±10 b·min-1 of predicted max, and respiratory exchange ratio (RER) >1.0). 
However, Saynor et al., (2013a), reported that secondary criteria often 
underestimated the true maximum in children with CF. The authors utilised a 
supramaximal (Smax) protocol as an addition to a protocol with only an incremental 
test to exhaustion, such as the widely used Godfrey protocol (Godfrey et al., 
1971).  
Figure 2.5. Ramp and Smax protocol. A: 3 min warm up, 20 W. B: Incremental 
ramp test, at individualised increments. C: ~5 min unloaded pedalling recovery. 
D: 10 min recovery off the bike. E: 3 min warm up at 20 W. F: Smax bout, 110 % 
peak power attained during B. G: ~3 min unloaded pedalling recovery 
(reproduced from Williams et al, 2014). 
 
Studies have concluded that incremental tests to exhaustion that make use of 
secondary criteria can underestimate	V̇O2max in healthy populations (Sansum et 
al., 2019; Poole et al., 2008). Therefore, Smax variation of CPET, which can be 
appended onto the end of most protocols as it includes both an incremental test 
35 
to exhaustion prior to a Smax bout (Fig. 2.5), can determine a valid and reliable V̇O2max in CF (Saynor et al., 2013a; Saynor et al., 2013b). Saynor and colleagues 
(2013a) confirmed that a bout at 110 % of peak power attained in an incremental 
test to exhaustion could verify the ‘true’ and confirm attainment of	V̇O2max. Further, 
a more recent study by Saynor and colleagues (2018) has confirmed the Smax to 
be safe and well tolerated in both children and adults with varying severities of 
CF. The above study by Saynor et al., (2018) had a relatively small sample 
population (45 participants), therefore a larger observational study may be 
required to confirm this conclusion. The ramp stage of the protocol increases in 
increments individualised to each of the participants (10-25 W∙min-1) based on 
previous prediction equations for peak power (Hulzebos et al., 2012) to ensure 
test duration lasts between 8-12 min. Due to the Smax being in the upper region 
of the severe exercise intensity domain, it generally lasts between 1-4 mins. The 
Smax bout has been validated to determine a ‘true’ V̇O2max in healthy adults 
(Dalleck et al., 2012). Sansum et al., (2019) reported that the Smax verified V̇O2max 
in 128 healthy children, and verification is not affected by sex, body mass or 
cardiorespiratory fitness. Furthermore, in a recent retrospective analysis 
including children and adults with mild to severe CF, the Smax produced a valid 
measure of V̇O2max in 86 % of children and 96 % of adults (Causer et al., 2018). 
Traditional controversial criteria for determining V̇O2max such as HR, RER and 
[BLa] can now be replaced by the Smax in healthy children (Sansum et al., 2019) 
and children/ adults with mild to severe CF (Saynor et al., 2013a). 
2.4 Cystic fibrosis and exercise capacity 
Exercise capacity or V̇O2peak has been shown to be a key indicator of mortality in 
the CF population independent of lung function (Hulzebos et al., 2014; Pianosi et 
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al., 2005a; Moorcroft et al., 1997; Nixon et al., 1992). Moorcroft et al., (1997) 
reported V̇O2peak significantly predicted mortality in 67 adult CF participants, 
however it was not more useful than FEV1. Conversely, Nixon and colleagues 
(1992), identified V̇O2peak as a significant predictor of mortality and FEV1 did not 
improve the relationship in the model. A meta-analysis, including 551 patients 
with CF, concluded a lower V̇O2peak was significantly associated with a 5-fold 
relative risk increase in mortality (Vendrusculo et al., 2019).  
 
Table 2.2. Generic training guidelines for CF (Reproduced from Williams et al., 
2010). 
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There are also reports that V̇O2max is associated with quality of life (de Jong et al., 
1997) and reduced hospitalisation in children with CF (Perez et al., 2014). 
Promoting a higher exercise capacity can improve quality of life for people with 
CF by helping to clear mucus and increase tolerance of everyday physical tasks 
(Cystic Fibrosis Trust, 2018e; de Jong et al., 1997). Despite this knowledge there 
are still no clear and precise guidelines for PA and exercise in CF due to a lack 
of well controlled trials and large differences amongst protocols (Bradley and 
Moran, 2008). Williams et al., (2010) provided a useful table of general 
recommendations (Table 2.2), which can be used to help create a more 
individualised programme by clinicians. A meta-analysis, including data from 17 
centres and 726 patients worldwide, reported contradictory evidence regarding 
how specific exercise can be beneficial to CF patients. Nevertheless, the 
overriding message is that there is no evidence to actively discourage exercise 
in children and adults with CF (Radtke et al., 2017).  
Children with mild CF have been shown to have a lower V̇O2peak (- 3.2 mL∙kg-
1∙min-1; -7.6 mL∙kg-1∙min-1) than their healthy peers (Vandekerckhove et al., 2017; 
Saynor et al., 2014 respectively), which is linked to disease severity. Cross 
sectional data have shown that lower V̇O2peak is significantly associated (p = 
0.0001) to a lower FEV1 in children and adolescents, unfortunately, the authors 
failed to report the correlation statistic (Pianosi et al., 2005a). Pianosi and 
colleagues (2005b) collected data in CF children (aged 7-16 years) over a 5-year 
period. They found that in children, V̇O2peak increased with age but adolescents 
(and those with FEV1 < 80 % predicted) observed a fall in V̇O2peak; those with FEV1 
> 80 % predicted tended to maintain V̇O2peak. However, the authors did not consider 
other clinical factors that could influence results such as genotype, nutritional and 
maturational status, therefore we cannot infer causality from these results. In 
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contrast, in a paediatric (8-18 y) longitudinal study over 2 years reported V̇O2peak 
to increase over the observation period, with change in FEV1 and FFM explaining 
47 % of the variance of the change in absolute V̇O2peak (Klijin et al., 2003). 
However, the authors in this study failed to account for maturity status, therefore 
the increase in V̇O2peak may have been the result of multiple other factors such as 
training and puberty. Currently, there is limited longitudinal evidence reporting the 
response of exercise related variables in children with CF. Two of the most 
important factors relating to mortality in CF, lung function and a body size/ 
nutrition, have been accounted for in the study by Klijin et al., (2003), yet there is 
still 53 % of variance in CF V̇O2peak that is unaccounted for.  
There are many conceivable factors that limit exercise capacity; however, it is 
unknown which processes in the oxygen transport and utilisation pathway are the 
biggest contributors to exercise intolerance for children and adults with CF (Fig. 
2.6). Due to the primary nature of CF causing obstruction in the airways, there is 
impairment in the lungs during exercise. People with CF experience a reduced 
reserve volume to total lung capacity ratio (RV/TLC), which can cause 
hyperinflation and therefore increased dead space (Hulzebos et al., 2014). This 
increases demand on the inspiratory muscles to maintain	V̇&, increasing the 
oxygen cost, and therefore causing people with CF to have a higher ventilatory 
contribution to V̇O2peak, thus reducing the respiratory muscle endurance (Leroy et 
al., 2011). Additionally, dynamic hyperinflation has been shown to reduce 
exercise capacity in other diseased populations (Zhao et al., 2016). Furthermore, 
adults and adolescents with CF have an observed higher respiratory muscle 
strength than predicted because of the greater work of breathing (Dunnink et al., 
2009). Moorcroft et al., (2005) found that adults with mild or moderate CF had 
similar scores for ventilatory parameters as the healthy controls, reporting muscle 
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soreness as the reason for termination. In severe CF, Moorcroft et al., (2005) 
reported the opposite, suggesting that it is only in severe CF that lung function is 
the main reason for exercise intolerance. In addition, ventilatory parameters 
(such as FEV1), only explain approximately one third of reduced exercise capacity 
in CF suggesting other factors contribute to reduced exercise capacity (Pastre et 
al., 2014).  
 
 
 
 
 
Figure 2.6. The oxygen transport and utilisation pathway showing the integration 
of muscular, cardiovascular and pulmonary systems (reproduced from 
Wasserman et al., 1999). 
 
As ventilatory parameters cannot explain fully the reduced exercise capacity in 
CF, researchers have investigated the role of cardiovascular function. Figure 2.6 
shows the integration of the heart, lungs and muscles in the oxygen transportation 
and utilisation pathway that may contribute to reduced exercise capacity. It has 
been suggested that cardiopulmonary factors may provide insight into the 
limitations of exercise for CF patients. During maximal exercise in children with 
CF there is a reduced stroke volume (SV) which is not sufficiently compensated 
for by HR, resulting in a reduced cardiac output (+̇; Rosenthal et al., 2009), 
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whereas during submaximal exercise HR can compensate sufficiently. Although 
Rosenthal and colleagues assessed +̇ indirectly through the Fick equation (Fig. 
2.7), other studies have shown that adults with CF elicit right ventricular (RV) 
abnormalities (Ionescu et al., 2001) measured through echocardiography. 
Ionescu et al., (2001) concluded that RV dysfunction is positively correlated with 
disease severity, which can in turn influence exercise tolerance. In a study by 
Giacchi et al., (2015) it was reported children with CF to be vulnerable to heart 
impairment and hypothesised that this was because of the consistent chronic 
inflammation due to declining lung function. Furthermore, children with CF cannot 
increase RV ejection fraction sufficiently during exercise (Benson et al., 1984), 
which increases the risk of pulmonary hypertension and exercise intolerance 
(Lewis et al., 2013). However, it is unknown whether children with CF elicit 
pulmonary hypertension during exercise and if this dysfunction influences 
exercise intolerance. 
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Figure 2.7. Schematic based on the Fick Equation to highlight what is known and not known about contributors of exercise capacity/ 
aerobic fitness. Hb; Haemoglobin. O2; oxygen. PO2; partial pressure of oxygen. Q; cardiac output. a-vO2 difference; arterial-venous oxygen 
difference. !̇O2; maximal oxygen uptake. 
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The CFTR protein has been shown to present in skeletal muscle cells as well as 
in the pulmonary and digestive systems (Lamhonwah et al., 2010; Divangahi et 
al., 2009). It is known that muscle strength is positively related to anaerobic (Boas 
et al., 1996) and aerobic (Klijn et al., 2003; de Meer et al., 1999) capacity. Muscle 
strength is reduced in young CF males (Hussey et al., 2002) and when muscle 
size is accounted for there is still ~5 mL∙cm2∙min-1 difference in V̇O2max between 
CF and controls (Moser et al., 2000). However, this study used cross sectional 
area (CSA) as a measure for muscle size and scaled using the ratio standard 
method (RSM). CSA is an indirect measure of muscle volume and the RSM has 
been shown to over scale data, causing heavier children to be penalised and 
lighter children to have their fitness elevated (Tanner, 1949). Allometric scaling 
uses an equation (Y=a.Xb) to describe the specific relationship between the 
physiological variable (i.e. V̇O2) and a unit of body size (i.e. fat free mass) to more 
appropriately remove the influence of body size (Welsman and Armstrong, 2000). 
Where Y = physiological variable; a = proportionality constant; X = body size 
measure; and b = power function.  
Some studies have found evidence for impaired skeletal muscle function 
regardless of MM (Erickson et al., 2015; Rosenthal et al., 2009; de Meer et al., 
1995). Erickson et al., (2015) reported an age dependent inverse relationship with 
oxidative capacity and age-related disease progression. Conversely, Werkman 
et al., (2016) found that there were no metabolic constraints in muscle oxidative 
capacity. However, both of the aforementioned studies had small cohorts of 
participants (13 and 10, respectively), measured different outcomes and the 
study by Erickson et al., (2015) used older participants than Werkman et al., 
(2016), making it difficult to compare the two. Furthermore, periods of greater 
inflammation such as infection of Pseudomonas aeruginosa, has been shown to 
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cause reduced muscle strength and exercise capacity in adolescent CF (Van de 
Weert-van Leeuwen et al., 2012; Divangahi et al., 2009). When whole body 
exercise is undertaken, children with mild to moderate CF appear to elicit no 
differences in the rate of oxygen extraction at the skeletal muscle level compared 
to healthy matched controls (Saynor et al., 2014). This leads to the conclusion 
that oxygen delivery and cardiovascular factors are the primary limiting factors in 
the skeletal muscles (Saynor et al., 2014; Rosenthal et al., 2009). In contrast, a 
later study by Saynor and colleagues (2016) proposed that the changes in 
aerobic metabolism are intensity dependent, impairments occurring during 
heavier intensities, linking to an impairment in O2 extraction and utilization in 
pediatric CF populations. Most of the literature bases its findings on mild to 
moderate CF, little or no evidence exists into skeletal muscle metabolism during 
exercise for those with severe CF (Werkman et al., 2016; Van de Weert-van 
Leeuwen et al., 2013). Few studies recruit severe CF patients largely due to 
pragmatic reasons, such as ability to perform the test. This makes it difficult to 
effectively research all aspects of CF, however it may be that findings would be 
similar but exacerbated in severe CF.  
2.5 Sex differences and exercise capacity 
Previous literature has shown that mortality of CF is largely dependent on 
nutrition or body mass index (BMI; body mass in kg over stature2 in m) (Vieni et 
al., 2013; Fogarty et al., 2012; Liou et al., 2001; Huang et al., 1987), lung function 
(Liou et al., 2001; Corey et al., 1997; Moorcroft et al., 1997; Kerem et al., 1992; 
Nixon et al., 1992), sex (Liou et al., 2001; Corey et al., 1997; FitzSimmons, 1993) 
and exercise capacity (Radtke et al., 2017; Pianosi et al., 2005). As both sex and 
exercise capacity are predictors of mortality, the relationship between the two 
factors required exploration. It is known that exercise capacity, measured using 
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V̇O2max, differs between sexes in healthy children (McNarry et al., 2015), however 
there is limited evidence in CF populations. 
In a population of 248 healthy children aged 8-11 y, Dencker et al., (2007) 
reported V̇O2peak to be higher in boys than girls, dependent on whether V̇O2 was 
expressed using scaling (8%) or in absolute terms (18%). Other studies have 
shown absolute values for V̇O2peak are ~20 % lower in females at a given age. 
When normalizing for BM, Armstrong et al., (1997) reported significantly higher V̇O2peak in boys than girls (adjusted V̇O2peak means of 1.76 L·min-1 and 1.52 L·min-
1, respectively). However, Davies et al., (1972) proposed that normalizing for 
body mass may be inappropriate as V̇O2max is related to the volume of muscle 
utilized during exercise in children. Thus, the percentage difference V̇O2peak is 
minimised to ~1 % when normalised MM between males and females (Welsman 
et al., 1997). In children with CF, when normalised for BM, males had higher V̇O2peak (+3.7 mL·kg-1·min-1 on average) than females (Pianosi et al., 2005a). It is 
unknown whether males with CF have a higher V̇O2peak than females with CF 
when normalised for FFM or MM as previous literature fails to report results for 
each sex. 
Many CF clinics do not take measurements of fat mass and FFM, possibly due 
to time constraints and the number of additional assessments required and their 
validity and reliability. However, fat mass and FFM have different properties such 
as conductivity, permittivity, and density (all greater in FFM). CF patients have an 
increase in fat mass and muscle wasting in comparison to healthy controls. In 
healthy individuals, females have higher proportions of fat mass than males 
suggesting females with CF could be even more likely to have higher proportions 
of fat mass than healthy males, which may contribute to the increased mortality 
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of females with CF. Therefore, it could be invalid to measure and compare 
participants based on whole body mass when compositions could differ between 
two children of the same total body weight. Furthermore, Singer and colleagues 
(2014), reported fat mass to be an inflammatory marker in children. Inflammation 
contributes to cardiovascular disease and insulin resistance (Dedoussis et al., 
2010; Berg et al., 2005) suggesting healthy females may be at a higher risk of 
developing other diseases than males, due to their increased proportions of fat 
mass. However, Singer et al., (2014) used a cross sectional design to establish 
causality; a longitudinal approach may be more appropriate to determine the 
causality between fat mass and inflammatory markers. Furthermore, this study 
did not include people with CF, who are already susceptible to diseases such as 
diabetes (Zirbes and Milla, 2009). It would therefore be prominent to identify 
whether females with CF are at a higher risk of developing diseases, which may 
contribute to their higher mortality.  
Many studies have suggested FEV1%predicted (Corey et al., 1997; Kerem et al., 
1992) to be the best predictor of mortality in children, adolescents and adults with 
CF (Kerem et al., 1992; Nixon et al., 1992). For a given value of FEV1, females 
have a higher mortality, whilst risk of death at an FEV1 between 20-30 % is 18 % 
higher in females (Kerem et al., 1992). This is supported by Corey et al., (1997) 
who reported that females have a steeper slope of decline in FEV1%predicted than 
males; a difference of ~20 % FEV1 predicted at the age of 30. However, this sex 
difference was only evident after 5 years of age meaning other factors could be 
influential. Habitual PA has been shown to help slow the rate of decline of lung 
function and can increase FEV1 in females, indicating there may be a sex specific 
response to PA and/or exercise. However, reports in the CF literature show levels 
of PA to decline during childhood and adolescence, with females becoming less 
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physically active than males during the pubertal years (Selvadurai et al., 2004). 
This reduction in PA in females with CF during adolescence may have a 
deconditioning effect on the body, as PA has been suggested to play a role in 
maintaining exercise capacity in CF (Savi et al., 2015), resulting in a lower 
exercise capacity than their male counterparts. This could partly explain why 
increasing habitual PA in females has a greater influence on lung function than 
in males. 
Although previous studies have reported that pulmonary function may partially 
account for the increased risk of mortality in females with CF, when removed as 
a factor, females still have a higher mortality rate (~60 %; Rosenfeld et al., 1997). 
Independent of lung function, a reduced exercise capacity has been shown to be 
a predictor of mortality in children, adolescents and young people with CF 
(Hulzebos et al., 2014; Nixon et al., 1992). It is well established that females with 
CF are at a greater risk of mortality than their male counterparts at any age (Corey 
et al., 1997), however sex differences are yet to be explored in relation to exercise 
capacity despite being an additional predictor of mortality (Hulzebos et al., 2014; 
Pianosi et al., 2005; Moorcroft et al., 1997; Nixon et al., 1992). In support, 
Werkman et al., (2014) identified that work peak and sex were significant 
predictors of V̇O2peak, therefore by extrapolation highlighting that there are sex 
differences in exercise capacity in CF.  
Hulzebos et al., (2014) reported the peak ventilatory equivalent ratio of oxygen 
(V̇E/V̇O2), an indication of ventilation required for a given V̇O2, to be a significant 
predictor of mortality, with higher values for those with poor survival. This study 
described a normal ventilatory drive in adolescent CF, but a higher carbon dioxide 
(CO2) production during exercise as result of greater carbohydrate (CHO) 
oxidation compared to healthy controls. However, they did not identify whether 
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this value was significantly different between sexes. It is possible that females 
with CF have significantly different V̇E/V̇O2 to males, due to differences in CHO 
oxidation, which contributes to higher mortality. Although, in healthy children it 
has been reported that there are no significant sex differences in V̇E/V̇O2 
(Armstrong et al., 1997). 
Whilst there is some literature that reports sex differences in relation to exercise 
capacity in CF children, few focus on this parameter as a key objective. Given 
that females with CF have higher mortality rates and the evidence in healthy 
children regarding a lower exercise capacity in females, it would be prominent to 
assess this area of research in CF. This line of enquiry may help to produce 
effective exercise management for females with CF to improve mortality to equal 
that of males with CF.  
2.6 Research questions 
Q1: What effect does disease status, as defined by FEV1, have on sex differences 
in cardiopulmonary exercise test outcomes? 
Q2: What effect does age have on sex differences in cardiopulmonary exercise 
test outcomes? 
Q3: What effect does ratio standard and allometric scaling for different body size 
variables (body mass, stature and body surface area) have on sex differences in V̇O2peak? 
Q4: Are sex differences in V̇O2peak (absolute and scaled) apparent after adjusting 
for lung function and nutritional and maturity status?  
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3. General Methods 
3.1 Ethical approval 
This thesis is a retrospective analysis and has been awarded Health Research 
Authority (HRA) approval (Appendix A). Ethics approval for the access to the 
retrospective data was obtained from the University of Exeter, Sport and Health 
Sciences Ethics Committee (Appendix B). All exercise and measures were taken 
as part of standard care of CF patients at the Royal Devon and Exeter NHS 
Foundation Trust Hospital (RD&E). Due to the retrospective nature of this thesis, 
no patients were approached to be a part of the present study but HRA and ethics 
approval have been sought to ensure it is in line with patient confidentiality and 
data protection laws. All adult patients (> 18 y) provided prior ethical consent, 
whilst paediatric patients (≤ 17 y) provided assent and parents or carers provided 
informed consent.  
3.2 Protocol 
Following HRA and ethics approval, files were extracted from the hospital server 
onto an encrypted memory stick. Following transport to the University site 
(University of Exeter, St. Luke’s campus) analysis and interpretation was carried 
out.  
3.3 Study participants  
Fifty-two young people (29 males and 23 females, 16.62 ± 4.62 y and 17.52 ± 
5.27 y; stature, 166 ± 15 cm and 157 ± 9 cm; body mass, 61.31 ± 18.05 kg  and 
53.99 ± 12.50 kg, respectively) with CF that have undergone a CPET at the RD&E 
as part of their annual review were included (Fig. 3.1). Patients were identified by 
staff at the hospital and anonymised prior to use for the present study. Patients 
were considered to have CF if tested positive for a sweat test (sweat Cl- > 60 
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mmol·L-1 > 100 mg sweat) and in 47 of 52 participants, genotyping was used. A 
total of 46.2 % of the study population were homozygous for F508del mutation 
compared to 50.2 % of the UK population recorded in the CF Trust registry (Cystic 
Fibrosis Trust, 2017c). Furthermore, only 19.2 % of the study population 
presented CFRDM compared to the 32 % and < 25 % reported in adults and 
children respectively (Cystic Fibrosis Trust, 2017c). CFRDM was diagnosed by 
an oral glucose tolerance test.  
Measuring fecal elastase-1 can identify exocrine status in CF, normal function is 
described as 200 to > 500 µg E1·g-1 stool, whereas mild to moderate insufficiency 
is 100 – 200 µg E1·g-1 stool (National Health Service, 2018). Approximately 79 
% of the study population were identified as pancreatic insufficient. 
Pseudomonas Aeruginosa is considered chronic if the patient has had 3 or more 
infections in 12 months (National Institute for Health and Care Excellence, 2018). 
In this study population there were on average 1 ± 2 infections per year. 
3.3.1 Inclusion and exclusion criteria. Only those who were considered 
clinically stable by staff at the hospital were asked to perform a CPET. Patients 
were free from; musculoskeletal injury, pulmonary exacerbations and intravenous 
(IV) antibiotics, or at the end of the IV course. Furthermore, patients were willing, 
able and had the mental capacity to undergo testing. Patients were only included 
if between 8 – 25 years old.  
Some patients were unable to perform the test due to other complications such 
as bowel cancer, hemoptysis and in some cases obesity where they could not 
safely perform on a bike and therefore were not included. Participants who were 
infected with non-tuberculosis mycobacteria could not use the gas analyser due 
to hygiene and risk of cross infection. Therefore, these patients underwent the 
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protocol without gas analysis, V̇O2 was then estimated from peak work rate using 
the equation from Werkman et al., (2014). These patients were not included in 
the present thesis as measures of gas exchange could not be reported.  
 
 
 
 
 
 
 
 
 
Figure 3.1. Patient inclusion flow diagram.  
3.4  Age 
Age was calculated as a decimal to the nearest 0.01 year. This indicates the age 
at completion of the CPET, the difference between date of birth and date of the 
exercise test. To identify the effect of age in binary terms on sex differences in 
CPET outcomes and run a two-way ANOVA, age was split into tertiles. Groups 
were created with 17 (9 male), 18 (13 male) and 17 (7 male) participants, average 
age of 11.52 y (8.82 - 13.84 y), 16.77 y (13.85 – 18.54 y) and 22.79 y (18.55 – 
25.10) respectively. 
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3.5 Maturity 
Pubertal stages based on secondary sex characteristics (based on Tanner 
criteria), the most common way of reporting sexual maturity, were not reported in 
the retrospective data, therefore years from peak height velocity (PHV) was used 
as a marker of (somatic) maturity. PHV can be used as a marker of somatic 
maturity by identifying the highest growth velocity in stature during adolescence. 
Often, predictive equations for PHV require sitting height, however as the hospital 
did not record this, the following equations were used based on stature and age 
for the children and adolescents (Moore et al., 2015): 
Boys Peak Height Velocity (y) = -7.999994 + [0.0036124 x age (y) x stature 
(cm)]  
Girls Peak Height Velocity (y) = -7.709133 + [0.0042232 x age (y) x stature 
(cm)] 
These equations were reported to be valid in healthy boys and girls (R2 = 0.906, 
SEE = 0.514 and R2 = 0.898, SEE = 0.528 respectively; Moore et al., 2015). 
However, it has yet to be determined if these equations are valid for use in CF 
populations. Maturity was then identified as pre (< -1 y), post (> +1 y) and circa 
(-0.99 to +0.99) PHV due to concerns that the error is too great as a continuous 
score (Mirwald et al., 2002). There is increasing evidence that skeletal age of the 
hand-wrist is preferred to account for maturity (Malina, 2011), however due to the 
retrospective nature of the present analysis this parameter was not available. 
Participants aged 18 y and above were considered an adult, and therefore were 
labelled a post PHV for analysis. 
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3.6 Anthropometry  
All measures were taken within the RD&E by clinic nurses or physiotherapists 
prior to the exercise test. Typically, sportswear was worn, and footwear was 
removed in all cases.  
3.6.1 Body mass. Body mass was measured using electronic scales (Seca 220; 
Vogel & Halke, Hamburg, Germany) to the nearest 0.01 kg. 
3.6.2 Stature. Stature was measured to the nearest 1 cm. Participants stood 
upright on a stadiometer (Seca 220; Vogel & Halke, Hamburg, Germany) with 
their heels against the back and feet together. Gentle pressure was applied to 
the mastoid process and body of mandible, whilst patients were instructed to 
stand straight and look forward.  
3.6.3 Body mass index. BMI was calculated from the stature and weight 
measures using the following equation:  
BMI = body mass (kg) / stature2 (m) 
BMI was reported both as a continuous score and into risk categories. 
Participants aged 18 y and above were categorised as: < 18.49 kg·m-2 = 
underweight; 18.50 – 24.90 kg·m-2 = healthy; 25.00 – 29.90 kg·m-2 = overweight, 
> 30 kg·m-2 = obese. The Cystic Fibrosis Foundation (2019) recommends men 
and women should maintain a BMI of at least 22 and 23 kg·m-2 respectively. 
Those aged below 18 y were classified using cut offs for thinness (Cole et al., 
2007) and fatness based on centile curves (Cole et al., 2000). Categories were 
used to normalise the influence of a mixed adult and paediatric population. 
3.6.4 Body surface area. BSA was calculated using the following equation from 
Haycock et al., (1978): 
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BSA (m2) = body mass0.5378 (kg) x stature0.3964 (cm) x 0.024265 
This equation is known to reduce the underestimation of child and infant surface 
area as seen in formulas from Du Bois and Du Bois (1916). The equation was 
developed on multiple ethnic groups (including Caucasian, the likely majority in 
this study cohort) and on both healthy and clinical populations. 
3.7 Pulmonary function 
FVC and FEV1 were collected via a spirometer (Micromedical Microloop 3535, 
Numed, Sheffield, UK) and performed to NHS guidelines. Patients were seated 
with a soft nose clip to prevent air escaping through the nose. Patients may have 
been asked to have a couple of practice attempts prior to the test. During the test 
patients were asked to inhale fully and close lips tightly around the mouthpiece 
before exhaling as quickly and forcefully as possible. Spirometry tests were 
repeated on average three times per patient, with a minimum of 30 s between 
tests, to ensure a reliable result. 
FVC%predicted and FEV1%predicted were calculated by using normative values stated 
by Quanjer et al., (2012) based on sex, ethnicity and body size. In the case that 
only absolute values were obtained, % predicted was calculated using a free to 
download desktop calculator from the Global Lung Initiative website as suggested 
by Quanjer et al., (2012). Further to this, FEV1%predicted was categorised into mild 
(> 70.0 %), moderate (40.0 – 69.9 %) and severe (< 39.9 %) lung function (Cystic 
Fibrosis Foundation, 2009) for further descriptive data relevant to the clinical 
setting. For the purpose of running a two-way ANOVA to identify the effect of 
disease status on sex differences in CPET outcomes, FEV1%predicted was split into 
tertiles as FEV1 categories contained a high proportion (79 %) of participants in a 
single category. 
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3.8 Cardiopulmonary exercise testing 
3.8.1 Safety and cross infection. As these tests were conducted as part of 
routine clinical care, all procedures were completed in line with standard clinical 
practice. Patients did not interact or come to contact with one another at either 
clinic or physiotherapy departments. Post CPET, all equipment was cleaned with 
antibacterial wipes and the environment sterilised. At least 1 hour was left 
between each patient to control for cross infection. 
Patients were monitored by a physiotherapist throughout testing for signs of 
significant symptoms (i.e. dyspnoea identified using the Borg scale). Nurses and 
medical staff were aware testing was taking place and supplemental O2 was 
available if necessary.  
3.8.2 Protocol. CPETs were performed on cycle ergometers (Lode Excalibur or 
Lode Corival, Groningen, The Netherlands) at the RD&E. All CPETs involved an 
incremental ramp to exhaustion and 47 of 52 participants completed a 
supramaximal verification stage as suggested by Saynor et al., (2013a) to 
determine a valid V̇O2max (Fig. 2.5). Patients performed a 3 min warm up at ~20 
W prior to the incremental ramp stage. For the ramp, the rate of increase (10-25 
W∙min-1) was predetermined and individualized for each participant based on 
their PA and clinical status to ensure the duration of the ramp lasted between 8-
12 min. Patients were encouraged to maintain a cadence of ~60-80 rev∙min-1. 
When cadence dropped > 10 rev∙min-1 for 5 consecutive seconds despite 
encouragement, volitional exhaustion was assumed and the ramp stage 
concluded. A period of active recovery (~5 min) at 20 W followed. At least 10 min 
passive recovery preceded the Smax stage. The Smax phase consisted of another 
3 min warm up at ~20 W prior to a step transition to 110 % of WRpeak attained 
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during the incremental ramp test. When volitional exhaustion occurred, typically 
after ~3 min, an optional 5 min active recovery (~20 W) was completed before 
the termination of the CPET (Fig. 2.5).  
3.9 Gas exchange parameters 
Metabolic gas analysers (Metalyzer 3B Cortex, Biophysik, Leipzig, Germany) 
were used to measure parameters of gas exchange (V̇O2, V̇CO2, V̇E) and 
calibrated to known concentrations of gases. A 3 L calibration syringe (Hans 
Rudolph, Kansas City, MO, USA) was used to calibrate the turbine volume 
transducer. At rest and exercise, breath by breath pulmonary gas exchange and 
ventilation was measured through a face mask, 1 s averages were recorded and 
subsequently averaged into 10 s for the use of analysis for all parameters. The 
accuracy of the gas analyser was 2 % (O2) and 0.1 % (CO2) when calibrated 
according to manufacturer’s instructions.  
3.10 Heart rate 
HR was measured continually throughout the CPET via a Bluetooth heart rate 
monitor (Polar T31 Heart Rate Strap, Polar Electro, Finland) strapped across the 
chest; around the base of the sternum and between ribs 5/6.  
3.11 Determination of parameters 
3.11.1 Determination of #̇O2peak. Breath by breath data were converted into 
templates and opened in MSF21 [purpose built software (LabVIEW, National 
Instruments, Newbury, UK).	V̇O2 was plotted against time as 10 s averages, the 
linear portion of the graph was isolated to plot a regression line (Fig. 3.2) to 
identify V̇O2peak. If the V̇O2 attained during the Smax was < 9 % greater than V̇O2peak 
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during the ramp stage, V̇O2 was verified as maximal, as suggested by Saynor 
and colleagues (2013a). 
% change in V̇O2 from ramp to Smax  
= [ (Smax V̇O2peak – Ramp V̇O2peak) ÷ Ramp V̇O2peak] x 100 
 As ~10 % of participants did not complete the Smax verification V̇O2peak was 
identified as the largest 10 s average V̇O2 value from the ramp test2. 
 
 
 
 
 
Figure 3.2. Example of plotting &̇O2 against time linear regression in MSF21 
(LabVIEW, National Instruments, Newbury, UK) to obtain &̇O2peak. Example data 
from a patient with cystic fibrosis. 
 
Time to exhaustion (TTE) was identified as time from the start of the ramp to 
exhaustion, the point at which the participant could no longer hold the cadence 
of ~60-80 rev∙min-1.  
Scaling of data in the paediatric population is important to identify a relative size 
free value for parameters such as	V̇O2peak. This helps to control for the influence 
 
 
2 As V̇O2peak and V̇O2max are used interchangeably in the literature, for the purpose of this thesis 
all highest V̇O2 data will be referred to as V̇O2peak. 
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of growth in children and adolescents (Baxter-Jones et al., 2005). Allometric 
scaling is considered to be the gold standard method whilst the RSM is still widely 
used. Prior to scaling, absolute V̇O2peak for each sex was plotted against BM, BSA 
and stature, producing a scatter plot to determine if scaling was required (i.e. a 
significant correlation would demonstrate scaling was required). In all cases the 
plots informed that scaling was required to produce size free values for V̇O2peak 
(Fig. 3.3). Body size variables (BM, BSA and stature) were then used to scale V̇O2peak for each sex using the RSM (Y/X), however scatter plots and correlations 
produced showed the RSM did not appropriately remove the influence of body 
size for stature in both males and females (Fig. 3.3). Log-linear regression 
analyses were then used to scale V̇O2peak via the allometric method, whereby sex 
and BM, sex and BSA, sex and stature, were entered as predictor variables in 
three separate regression models.   
The analyses produced a scaling exponent (b) which was used in the power 
function ratio to produce size free values of V̇O2peak (Fig. 3.3). Correlational 
analyses were run to confirm that measures were size free. The scaling 
exponents identified were:  
V̇O2peak/BM*b 
b = 0.82, 95% CI [0.470-1.178] 
V̇O2peak/BSA*b 
b = 1.29, 95% CI [0.726-1.843] 
V̇O2peak/Stature*b 
b = 2.42, 95% CI [1.090-3.751] 
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Figure 3.3. Scaling of body size parameters. Significant correlations denoted by 
*. Males r and p value denoted in top right corner of each graph; females denoted 
in the bottom right corner. 1; absolute V̇O2peak plotted against BM, BSA and 
stature. 1; absolute V̇O2peak plotted against a: mass, b: body surface area and c: 
stature. 2; ratio standard scaled V̇O2peak plotted against a: BM, b: BSA and c: 
stature. 3; allometrically scaled V̇O2peak plotted against a: BM, b: BSA and c: 
stature.	V̇O2peak; peak oxygen uptake. BM; body mass. BSA; body surface area. 
β; beta coefficient.  
 
3.11.2 Determination of other $̇O2 parameters. Functional V̇O2 gain was 
determined through regression of the linear profile of V̇O2 response versus power 
output during the ramp test. 
V̇O2 gain = ∆V̇O2 ÷ ∆WR 
Oxygen pulse, a marker of maximal stroke volume and therefore cardiac fitness, 
was identified using the following equation. 
Oxygen pulse = max (V̇O2 ÷ HR) 
3.11.3 Determination of the gas exchange threshold and respiratory 
compensation point. The RCP was visually identified using MSF21 as the first 
inflection point when plotting V̇E versus V̇CO2, when no inflection point could be 
visually identified, the RCP was not obtained. Once identified, the RCP was 
reported as a % of V̇O2peak. All data following the respiratory compensation point 
(RCP) were removed and a graph of V̇CO2 against V̇O2 was produced (Fig. 3.4 
A). The GET was identified using the V-slope method (Beaver et al., 1986); the 
intersection of two regression lines from a plot of V̇CO2 against V̇O2. In the case 
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that the GET could not be determined in this way, it was visually determined using 
the ventilatory equivalents for V̇O2 and V̇CO2 (Fig. 3.4 B). The GET was identified 
individually by two separate researchers in 1/3 of data sets (researchers were 
within 10 % of each other, therefore the remaining 2/3 of data was split between 
researchers for analysis). GET data were presented as an absolute value (V̇O2 
at the GET), GET relative to body mass and as a percentage of V̇O2peak.  
3.11.4 Determination of ventilatory drive. Using 10 s averages during the ramp 
protocol, the highest ventilatory equivalents at peak exercise were recorded to 
obtain V̇E/V̇O2 and V̇E/V̇CO2.To identify V̇E/V̇O2 and V̇E/V̇CO2 slopes, 10 s data 
from the entire ramp test was input into a computer programme (GraphPad Prism 
Version 7; GraphPad Software, 171 San Diego, CA) which generates the 
regression slope automatically by plotting V̇E vs V̇O2 and V̇E vs V̇CO2. 
3.11.5 Determination of $̇O2 reference values. V̇O2peak values obtained by the 
participants were compared to equations for calculating reference V̇O2peak values 
in healthy children (Bongers et al., 2014b). Comparisons between reference 
values and the participants in the present analysis were made through identifying 
percentage differences (see appendix C for individual reference values). 
Participants aged 18 y and above were considered an adult and therefore were 
not included in the analysis of reference values. 
Boys V̇O2peak (L·min-1) = (0.0033 x (age2)) + (0.1316 x age) + 0.084 
Girls V̇O2peak (L·min-1) = (-0.0022 x (age2)) + (0.2184 x age) – 0.4727 
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Figure 3.4. Example data of an individual with cystic fibrosis to determine the gas 
exchange threshold in MSF21 (LabVIEW, National Instruments, Newbury, UK). 
Respiratory compensation point, the point at which there is a steeper rate of 
minute ventilation [V̇E] vs. rate of carbon dioxide production [V̇CO2] (Beaver et al., 
1986), was removed before further analysis. A: Shows the inflection point 
identified by the software on the graph plotting V̇CO2 against oxygen uptake 
(V̇O2). The intersection of the yellow lines marks the disproportionate increase in V̇CO2 compared to V̇O2, and therefore the gas exchange threshold. B: Shows the 
visual determination of the ventilatory threshold using ventilatory equivalents of V̇O2 and V̇CO2 (identified on the graph by the intercept of the horizontal and 
vertical lines). 
 
A 
B 
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3.12 Statistical analyses 
Data are presented as mean and standard deviation unless otherwise stated with 
the alpha level set to p = 0.05 significance level. Descriptive statistics with mean 
sex differences in continuous outcome variables determined by independent t-
tests. For sex differences in clinical and CPET outcomes, estimates of effect size 
were calculated using Cohen’s D (0.2 = small effect; 0.5 = medium effect; 0.8 = 
large effect; Cohen 1998). Sex differences in categorical data were identified by 
the Mann-Whitney test after converting into ordinal data as the assumptions of 
Chi Square analysis were not met. Relationships were determined between 
clinical and exercise test parameters using Pearson’s correlation coefficient for 
the whole group and each sex separately. Correlations were considered to be; 
negligible r = (±) 0.00 to 0.30; weak r = (±) 0.30 to 0.50; moderate r = (±) 0.50 to 
0.70; strong r = (±) 0.70 to 0.90; or very strong r = (±) 0.90 to 1.00 as defined by 
Mukaka (2012). Bi lateral correlational analyses of V̇Epeak and age was identified 
by splitting the whole group into two equal groups (26 participants in each group) 
of age (< 17 y and ≥ 17 y).  
Separate two-way ANOVA’s were run on 52 participants to examine the effect of; 
sex (male/ female) and lung function (FEV1 tertiles) [research question 1]; and 
sex (male/ female) and age (tertiles) [research question 2] on different CPET 
parameters (dependent variable). For the purpose of analysis, age and lung 
function (FEV1%predicted) were categorised by tertiles to relate more closely to 
clinical classification of CF disease severity (i.e. mild, moderate and severe). 
Tertiles were split through: FEV1%predicted, < 77.48 = 1, 77.49 – 91.49 = 2, > 91.50 
= 3 (Fig. 4.6); Age (y), < 13.85 = 1, 13.86 – 18.55 = 2, > 18.56 = 3. Data were not 
skewed (identified from histograms and P-P plots) and Levene’s statistic was not 
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significant when based on the median, therefore the assumptions of normality 
and homogeneity of variances were met for the following analyses.  
Body size variables (BM, BSA and stature) were used to scale V̇O2peak for each 
sex using the RSM (Y/X). Log-linear regression analyses were used to scale V̇O2peak via the allometric method; sex and BM, sex and BSA, sex and stature, 
were entered as predictor variables in three separate analyses to produce a β 
coefficient. For the purpose of research question 3, independent t-tests were run 
to identify sex differences scaled V̇O2 values.  
To identify sex differences in absolute and allometrically scaled V̇O2 when 
controlling for age (y), PHV (pre, circa and post pubertal), BMI (underweight, 
healthy weight, overweight, obese) and FEV1 (% predicted) (research question 
4), ANCOVAs were utilised. Exploratory analyses were undertaken with the 
removal of PHV as a co variate. Assumptions of the ANCOVA; (1) independence 
of the co variate and treatment effect, (2) homogeneity of regression slopes, (3) 
normal distribution and (4) homogeneity of variance were met for all conditions. 
Partial eta squared effect sizes were defined as small = 0.1, medium = 0.3 or 
large = 0.5 (Cohen, 1988). 
All analyses were performed using SPSS v 25 (Chicago, Illinois, USA) and graphs 
created in GraphPad Prism 7 (GraphPad Software Inc., San Diego, California, 
USA). 
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4. Results 
 
4.1 Descriptive statistics 
4.1.1 Clinical Parameters. Of the 52 CF patients included, 46.2 % and 38.5 % 
were homozygous and heterozygous for F508del respectively. The median age 
of the whole group was 17.02 ± 4.89 y, 29 (55.8 %) of which were male. Stature 
and body mass were 162 ± 13 cm and 58.07 ± 16.12 kg, respectively. Stature 
was significantly higher in males than females. Males had a significantly higher 
FVC (L) and FEV1 (L) than females. Non-significant differences between males 
and females were noted in: Age (y), time between CPET and annual review (y), 
BM (kg), BSA (m2), BMI (kg·m-2 and categories), FVC%predicted and FEV1%predicted 
(Table 4.2). The paediatric population consisted of 12 girls and 19 boys, of which 
42 % were post pubertal. Whole group categorical data are exhibited in Table 
4.1. Full descriptive data of clinical outcomes, with significant sex differences 
identified from independent t-tests, are presented in Table 4.2. FVC or 
FVC%predicted was not recorded in two females and one male.  
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Table 4.1. Group frequencies of categorical clinical parameters. 
Variable Males Females Total (% of population) 
p 
value 
 
Genotype 
 
Homozygous 
Heterozygous 
Neither 
15 
10 
3 
9 
10 
0 
46.2 
38.5 
5.8 
0.367 
 
Pancreatic 
 
Sufficient 
Insufficient 
3 
23 
2 
18 
9.6 
78.8 
0.869 
 
FEV1 (% 
predicted) 
 
Severe 
Moderate 
Mild 
2 
2 
25 
0 
7 
15 
3.8 
17.3 
78.8 
0.208 
 
Diabetes 
 
None 
Impaired Glucose Tolerance 
CFRDM 
23 
1 
3 
12 
2 
7 
67.3 
5.8 
19.2 
0.032* 
BMI  
Underweight 
Normal 
Overweight 
Obese 
1 
19 
8 
1 
1 
17 
5 
0 
3.8 
69.2 
25 
1.9 
0.431 
 
Maturity 
Pre-Pubertal 
Pubertal 
Post Pubertal 
6 
4 
19 
2 
6 
15 
15.4 
19.2 
65.4 
0.776 
Chronic PA 
None 
1-5 
>5 
21 
5 
1 
16 
3 
2 
71.2 
15.3 
5.7 
0.810 
Significant sexes differences obtained using the Mann-Whitney test; significant p 
values highlighted in bold and *. Data presented as a frequency of sub-groups 
and a percentage of the whole study population. FEV1; Forced expiratory volume 
in 1 s. CFRDM; Cystic fibrosis related diabetes mellitus. BMI; Body mass index. 
PHV; Peak height velocity. Chronic PA; Chronic pseudomonas aeruginosa 
infection.
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Table 4.2. Sex differences in anthropometric and pulmonary function parameters.
Variable Whole Group Males Females .p Value Effect Size 
Age (y) 17.02 ± 4.89 16.62 ± 4.62 17.52 ± 5.27 0.514 0.182 
Time Between CPET and AR (y) 0.25 ± 0.32 0.23 ± 0.29 0.29 ± 0.35 0.517 0.187 
Stature (cm) 162 ± 13 166 ± 15 157 ± 9 0.027* 0.728 
BM (kg) 58.07 ± 16.12 61.31 ± 18.05 53.99 ± 12.50 0.104 0.446 
BSA (m2) 1.61 ± 0.29 1.67 ± 0.32 1.53 ± 0.22 0.086 0.510 
BMI (kg∙m-2) 21.70 ± 3.76 21.81 ± 3.92 21.56 ± 3.62 0.811 0.066 
FVC (L) 3.46 ± 1.26 3.89 ± 1.35 2.89 ± 0.88 0.005* 0.878 
FVC (L∙m-1) 2.10 ± 0.64 2.31 ± 0.13 1.83 ± 0.47 0.007* 1.392 
FVC (% Predicted) 90.48 ± 17.04 91.28 ± 18.38 89.41 ± 15.46 0.709 0.110 
FEV1 (L) 2.78 ± 1.08 3.14 ± 1.17 2.33 ± 0.77 0.006* 0.818 
FEV1 (L∙m-1) 1.69 ± 0.56 1.87 ± 0.60 1.46 ± 0.42 0.009* 0.792 
FEV1 (% Predicted) 83.66 ± 19.76 86.01 ± 21.01 80.70 ± 18.09 0.341 0.271 
Data are presented as mean ± SD. Significant differences between sexes are highlighted in bold and *. p value determined from 
independent samples T-Tests, alpha level = 0.05. Effect size = Cohen’s d. CPET; Cardiopulmonary exercise test. AR; Annual review. 
BM; Body mass. BSA; Body surface area. BMI; Body mass index; 0 = underweight, 1 = healthy weight, 2 = overweight, 3 = obese. FVC; 
Forced vital capacity. FEV1; Forced expiratory volume in 1 s.  
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4.1.2 Cardiopulmonary exercise test parameters. GET was identified in 47 of 
52 participants, unidentified in 2 males and 3 females. RCP could not be identified 
in 9 males and 10 females. HR was not picked up or recorded in 8 males and 11 
females. RER could be identified in all but 1 male participant. Mean TTE took 505 
± 142 s (sex differences reported in Table 4.3).  
Of the 47 participants that completed the Smax, 34 % of V̇O2peak were not verified 
by the Smax bout (62 % of males and 72 % females obtained true V̇O2max). No 
significant differences in Smax TTE were observed between males and females (p 
= 0.189). 
Absolute V̇O2peak was significantly (p < 0.001) lower in females than males (1.41 
± 0.38 L∙min-1 and 2.17 ± 0.82 L∙min-1 respectively) (Fig. 4.1). Compared to 
reference V̇O2peak values in healthy children, mean difference in this population 
was + 17.8 % and + 34.6 % for males and females V̇O2peak, respectively (p = 
0.010).  
  
 
 
 
 
 
 
Figure. 4.1. V̇O2peak distribution in males and females. Lines represent mean 
and standard deviation. Significant difference highlighted with an *. 
* 
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Males had a significantly higher mean than females in the following parameters: 
peak power; peak power ramp relative to body mass; TTE ramp; absolute V̇O2peak; V̇CO2peak; GET (absolute V̇O2 at GET); V̇O2 at GET relative to BM; V̇Epeak; 
tidal volume and oxygen pulse (Table 4.3). At peak V̇O2, females elicited 
significantly lower values than males for V̇CO2 (1.72 ± 0.58, 2.68 ± 1.14 L∙min-1, 
p = 0.001, respectively) and V̇E (61.34 ± 22.54, 100.35 ± 41.83 L∙min-1, p < 0.001, 
respectively).  
Ramp data revealed non-significant differences between males and females in: V̇O2 gain; GET % V̇O2peak; RCP % V̇O2peak; V̇E/V̇O2; V̇E/V̇CO2; V̇E/V̇O2 Slope; V̇E/V̇CO2 Slope; breathing frequency; RERpeak; and HRpeak (Table 4.3). 
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Table 4.3. Cardiopulmonary exercise test parameters with sex differences. 
Variable Whole Group Males Females p Value Effect Size 
Sub-maximal      
GET (L∙min-1) 1.07 ± 0.44 1.25 ± 0.50 0.83 ± 0.16 0.001* -1.131 
GET (mL∙kg-1∙min-1) 18 ± 5 21 ± 5 16 ± 3 < 0.001* -1.213 
GET (% VO2peak) 60.03 ± 9.32 59.28 ± 9.85 61.04 ± 8.68 0.528 0.190 
RCP (% VO2peak) 94.02 ± 4.14 94.45 ± 3.66 93.36 ± 4.86 0.466 -0.253 !̇E/!̇O2 Slope 48.36 ± 11.93 46.59 ± 11.24 50.51 ± 12.64 0.247 0.328 !̇E/!̇CO2 Slope 36.59 ± 5.21 35.52 ± 5.32 37.89 ± 4.89 0.107 0.464 
Maximal      
Peak Power (W) 164 ± 74 194 ± 78 126 ± 47 0.001* 1.056 
Peak Power (W∙kg-1) 2.79 ± 0.84 3.16 ± 0.78 2.34 ± 0.69 < 0.001* 1.114 
TTE (s) 505 ± 142 563 ± 139 432 ± 111 0.001* 1.041 !̇O2peak (L∙min-1) 1.83 ± 0.75 2.17 ± 0.82 1.41 ± 0.38 < 0.001* -1.189 !̇O2 Gain (mL∙min-1∙W-1) 6.99 ± 1.76 7.23 ± 1.78 6.75 ± 1.73 0.328 -0.100 !̇CO2peak (L∙min-1) 2.32 ± 1.03 2.75 ± 1.10 1.77 ± 0.60 < 0.001* -1.106 !̇E (L∙min-1) 89.52 ± 37.22 104.71 ± 40.49 70.37 ± 20.94 0.001* -1.065 !̇E/!̇O2 (L∙min-1) 68.32 ± 17.83 69.39 ± 19.72 67.02 ± 15.56 0.642 -0.133 
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Data are expressed as mean ± SD. Significant differences between sexes are highlighted in red and *. Alpha level = 0.05, p value obtained 
by independent samples T-tests. Effect size = Cohen’s d. !̇O2peak; Peak oxygen uptake. !̇O2 gain; Oxygen cost of exercise. !̇CO2peak; Peak 
carbon dioxide output. GET; Gas exchange threshold. RCP; Respiratory compensation point. !̇E; Minute ventilation. !̇E/!̇O2; Ventilatory 
equivalent for oxygen uptake. !̇E/!̇CO2; Ventilatory equivalent for carbon dioxide. !̇E/!̇O2 slope and !̇E/!̇CO2 slope; Ventilatory drive. TTE; 
Time to exhaustion. BF; Breathing frequency; RERpeak; Peak respiratory exchange ratio. HRpeak; Peak heart rate.  
!̇E/!̇CO2 (L∙min-1) 47.28 ± 5.72 46.40 ± 6.07 48.35 ± 5.20 0.230 0.345 
BF (breaths∙min-1) 60.78 ± 8.90 62.64 ± 9.80 58.43 ± 7.14 0.090 -0.491 
Tidal Volume (L) 1.79 ± 0.69 2.03 ± 0.73 1.48 ± 0.50 0.003* -0.879 
RERpeak 1.60 ± 0.33 1.66 ± 0.34 1.54 ± 0.31 0.189 -0.369 
HRpeak (b∙min-1) 177 ± 17 177 ± 19 176 ± 14 0.942 -0.060 
Oxygen Pulse (mL∙min-1) 11 ± 4 12 ± 5 8 ± 2 0.009* -1.050 
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4.1.3 Correlations between CPET and clinical parameters. For the whole 
group, a strong and positive correlation was observed between FEV1 (L) and GET 
(L∙min-1; r = 0.71, p < 0.001), and a moderate correlation was identified between 
FEV1 (L) and peak power relative to body mass (r = 0.63, p < 0.001).  
Simple linear correlation between age and V̇Epeak revealed a weak but positive 
correlation r = 0.32, p = 0.023, which remained significant when analyses were 
run separately for males (r = 0.435, p = 0.018) and females (r = 0.430, p = 0.040). 
Visual analysis of data points revealed V̇Epeak declines after ~ 18 y of age (Fig. 
4.2). Bi lateral correlational analyses showed a significant positive correlation 
between V̇Epeak and participants aged 8-16 y (r = 0.71, p < 0.001); and a significant 
negative correlation between V̇Epeak and participants aged 17-25 y (r = -0.515, p 
= 0.007). 
Pearson’s correlation analyses produced coefficients between clinical and V̇O2peak (absolute and relative) parameters for each sex (Table 4.4). V̇O2peak was 
significantly correlated to BMI in males only. BM, BSA and stature all significantly 
correlated to V̇O2peak in both males and females. Age did not significantly correlate 
with any V̇O2peak parameters.  
 
 
 
 
 
 
 
Figure 4.2. Correlation between minute ventilation and age. Solid linear line 
represents the visual point at which the positive correlation becomes negative.  
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Table 4.4. Correlations between clinical and !̇O2peak parameters in males and females. 
V̇O2peak parameter FEV1 % predicted FVC % predicted  Males  Females Males Females V̇O2peak (L∙min-1) r = 0.504, p = 0.005* r = 0.576, p = 0.004* r = 0.422, p = 0.025* r = 0.530, p = 0.013* V̇O2peak/ BM (L∙min-1·kg-1) r = 0.604, p = 0.001* r = 0.514, p = 0.012* r = 0.402, p = 0.034* r = 0.367, p = 0.102 V̇O2peak/ BSA (L∙min-1·m2) r = 0.622, p < 0.001* r = 0.623, p = 0.002* r = 0.466, p = 0.012* r = 0.507, p = 0.019* V̇O2peak/ Stature (L∙min-1·m-1) r = 0.562, p = 0.002* r = 0.597, p = 0.003* r = 0.461, p = 0.013* r = 0.508, p = 0.019* V̇O2peak/ BM*β  r = 0.622, p < 0.001* r = 0.576, p = 0.004* r = 0.439, p = 0.020* r = 0.448, p = 0.042* V̇O2peak/ BSA*β r = 0.634, p < 0.001* r = 0.587, p = 0.003* r = 0.545, p = 0.015* r = 0.444, p = 0.044* V̇O2peak/ Stature*β r = 0.631, p < 0.001* r = 0.586, p = 0.003* r = 0.500, p = 0.007* r = 0.416, p = 0.061 
Correlation coefficient identified from Pearson’s correlation analysis. Alpha level = 0.05. Significant p value highlighted in bold and *. !̇O2peak; peak oxygen uptake. FEV1; forced expiratory volume in 1 s. FVC; forced vital capacity. BM; body mass. BSA; body surface area.  
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4.2. Research question 1 and 2  
(The effect of disease status [1] and age [2] on CPET outcomes)  
Two separate two-way ANOVAs were run to address research aims 1 and 2; sex 
and lung function in one model, sex and age in another. An interaction effect of 
age tertiles and sex was noted for RCP (% V̇O2peak). No interaction effects of sex 
and FEV1 tertiles or sex and age tertiles were noted in any other of the ANOVAs. 
Main effects and effect sizes are reported below (Table 4.5). Mean and standard 
deviations of V̇O2peak (absolute and allometrically scaled) for each category of 
FEV1 tertiles and age tertiles are reported in figure 4.3. 
FEV1 tertiles significantly explains variance in: V̇O2peak (L∙min1), V̇O2peak/BM*β, V̇O2peak/BSA*β, V̇O2peak/Stature*β, TTE (s), V̇CO2peak (L∙min1), GET (% V̇O2peak) and 
tidal volume (L). Significant effects of age tertiles are noted in; V̇O2peak (L∙min1), V̇O2peak/Stature*β, peak power (W), TTE (s), V̇CO2peak (L∙min1), GET (L), V̇Epeak 
(L∙min-1), #̇E/#̇O2 (L∙min-1), tidal volume (L) and RERpeak (Table 4.5). 
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Figure 4.3. Mean oxygen uptake (a) and V̇O2peak allometrically scaled to body 
mass (b) body surface area (c) and stature (d) for males and females in each of 
the categories of 1: FEV1%predicted tertiles and 2: age tertiles. Vertical lines 
represent SD. Significant main effect of: sex = *; tertiles = #. 
* 
# 
* 
# 
* 
# 
* 
# * 
# 
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# 
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D 
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Table 4.5. Main effects and effect sizes of two-way ANOVA in young people with CF. 
Dependent Variable 
Independent variables: Sex and FEV1 Tertiles Independent variables: Sex and Age Tertiles 
Main Effect of 
Sex 
Main Effect of 
FEV1 Tertiles 
Adjusted 
R2 
Main Effect of 
Sex 
Main Effect of 
Age Tertiles 
Adjusted 
R2 V̇O2peak (L∙min1) p = 0.001* p = 0.020* 0.33 p < 0.001* p < 0.001* 0.51 V̇O2peak/BM*β p < 0.001* p = 0.013* 0.35 p < 0.001* p = 0.079 0.29 V̇O2peak/BSA*β p < 0.001* p = 0.010* 0.36 p = 0.001* p = 0.064 0.30 V̇O2peak/Stature*β p < 0.001* p = 0.005* 0.37 p = 0.001* p = 0.024* 0.34 V̇O2 gain (mL∙min-1∙W-1) p = 0.509 p = 0.160 0.07 p = 0.626 p = 0.182 0.01 
Peak power (W) p = 0.003* p = 0.090 0.23 p < 0.001* p < 0.001* 0.51 
Peak power (W∙kg1) p = 0.003* p = 0.087 0.27 p = 0.001* p = 0.451 0.19 
TTE (s) p = 0.002* p = 0.048* 0.28 p = 0.002* p = 0.022* 0.28 V̇CO2peak (L∙min1) p = 0.002* p = 0.050* 0.27 p < 0.001* p < 0.001* 0.52 
RCP (% VO2peak) p = 0.473 p = 0.261 -0.13 p = 0.046* p = 0.011* 0.32 
GET (L∙min1) p = 0.002* p = 0.619 0.17 p < 0.001* p < 0.001* 0.50 
GET (mL∙kg1∙min1) p < 0.001* p = 0.946 0.20 p = 0.001* p = 0.914 0.20 
GET (% V̇O2peak) p = 0.816 p = 0.035* 0.08 p = 0.733 p = 0.715 0.05 V̇Epeak (L∙min1) p = 0.002* p = 0.060 0.27 p < 0.001* p < 0.001* 0.53 #̇E/#̇O2 (L∙min-1) p = 0.886 p = 0.332 -0.02 p = 0.859 p = 0.034* 0.12 
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#̇E/#̇CO2 (L∙min-1) p = 0.539 p = 0.068 0.06 p = 0.401 p = 0.267 0.01 #̇E/#̇O2 Slope p = 0.310 p = 0.982 -0.08 p = 0.274 p = 0.958 0.01 #̇E/#̇CO2 Slope p = 0.221 p = 0.284 0.01 p = 0.120 p = 0.113 0.07 
Tidal volume (L) p = 0.013* p = 0.014* 0.26 p = 0.001* p < 0.001* 0.54 
BF (breaths∙min-1) p = 0.047* p = 0.336 0.03 p = 0.075 p = 0.312 0.02 
HRpeak (b∙min-1) p = 0.669 p = 0.610 0.05 p = 0.962 p = 0.223 -0.06 
RERpeak p = 0.405 p = 0.070 0.09 p = 0.420 p = 0.005* 0.23 
Oxygen Pulse (mL∙min-1) p = 0.033* p = 0.195 0.16 p = 0.009* p = 0.064 0.34 
Significant main effects are expressed by p value highlighted in bold and *. Alpha level set to 0.05.; V̇O2peak; peak oxygen uptake. V̇O2peak/BM*β maximal oxygen uptake scaled to body mass and raised to the exponent 0.82. V̇O2peak/BSA*β; maximal oxygen uptake scaled 
to body surface area and raised to the exponent 1.29. V̇O2peak/Stature*β; maximal oxygen uptake scaled to stature and raised to the exponent 
2.42. TTE; time to exhaustion. V̇CO2peak; peak carbon dioxide output. RCP; respiratory compensation point. GET; gas exchange threshold. V̇Epeak; peak minute ventilation. BF; breathing frequency. HRpeak; peak heart rate. RERpeak; peak respiratory exchange ratio.
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4.3. Research question 3 
(Effect of scaling on sex differences in !̇O2peak) 
 #̇O2peak allometrically scaled (Fig. 3.3) for BM, BSA and stature was significantly 
lower in females than males (Table 4.6). 
Table 4.6. #̇O2peak sex differences, with allometric scaling. 
Variable Males Females p Value V̇O2peak/BM*β 73.04 ± 19.57 53.28 ± 10.93 < 0.001* V̇O2peak/BSA*β 1108.06 ± 296.24 814.58 ± 159.05 < 0.001* V̇O2peak/Stature*β 627.77 ± 183.28 464.76 ± 86.69 < 0.001* 
 Data are presented as mean ± SD. Significant differences between sexes are 
reported from independent samples t-test and expressed by p value highlighted 
in bold and *. Alpha level set to 0.05.; #̇O2peak/BM*β; peak oxygen uptake scaled 
to body mass and raised to the power 0.82. #̇O2peak/BSA*β; peak oxygen uptake 
scaled to body surface area and raised to the power 1.29. #̇O2peak/Stature*β; peak 
oxygen uptake scaled to stature and raised to the power 2.42.  
 
4.4 Research question 4  
(Effect of scaling and co variates on sex differences in !̇O2peak) 
ANCOVAs were run on 52 participants to examine the effect of sex on absolute 
and scaled V̇O2peak when controlled for covariates; age (y), PHV (pre, pubertal 
and post), BMI (underweight, normal, overweight and obese) and FEV1%predicted 
as a continuous variable (Table 4.7).  
When run without covariates for absolute V̇O2peak, sex explained approximately 
25 % of variance. Inclusion of all co-variates explained 67 % of variance, with sex 
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accounting for ~21 %. Sex, PHV, BMI and FEV1%predicted had positive relationships 
with absolute V̇O2peak, age had a negative relationship. A significant effect of age 
(F (1, 46) = 12.151; p = 0.001) was noted when PHV was removed from the 
absolute V̇O2peak model. Age was non-significant with the removal of PHV in all 
other models. 
Age and BMI had a negative relationship with V̇O2peak/BM*β and V̇O2peak/BSA*β. 
PHV, sex and FEV1%predicted had positive relationships with V̇O2peak/BM*β and V̇O2peak/BSA*β. Age had a negative relationship with V̇O2peak/Stature*β, PHV, BMI, 
sex and FEV1%predicted had positive relationships with V̇O2peak/Stature*β. 
Sex and FEV1 significantly explained; 67 % variance in absolute V̇O2peak, 56 % 
variance in V̇O2peak/BM*β, 55 % variance in V̇O2peak/BSA*β and 52 % of variance 
in V̇O2peak/Stature*β (Table 4.7). Age, PHV and BMI did not significantly explain 
variance in any of the V̇O2peak parameters. 
Adjusted means were higher in males than females in all absolute and scaled V̇O2peak parameters (Fig. 4.4). Mean for males and females: V̇O2peak, 2.14 L·min-
1 and 1.44 L·min-1; V̇O2peak/BM*β, 7.28 ml·kg*0.82·min-1 and 54.23 ml·kg*0.82·min-1; V̇O2peak/BSA*β, 1094.812 ml·m2(*1.29)·min-1 and 831.292 ml·m2(*1.29)·min-1; V̇O2peak/Stature*β, 616.44 ml·m*2.42·min-1 and 479.04 ml·m*2.42·min-1, respectively.  
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Table 4.7. ANCOVA models for absolute and relative V̇O2peak for young people 
with CF. 
 
Co 
variates 
F p h%&  
Absolute V̇O2peak 
(adjusted R2 = 
0.67) 
 
   
 Age (1, 46) = 1.62 0.210 
 
 PHV (1, 46) = 21.01 < 0.001* 
 BMI (1, 46) = 1.69 0.200 
 FEV1 (1, 46) = 24.41 < 0.004* 
 Sex (1, 46) = 32.22 < 0.001* 0.41 V̇O2peak/BM*β 
(adjusted R2 = 
0.56) 
 
   
 Age (1, 46) = 3.128 0.084  
 PHV (1, 46) = 4.168 0.047*  
 BMI (1, 46) = 3.591 0.064  
 FEV1 (1, 46) = 22.825 < 0.001*  
 Sex (1, 46) = 15.374 < 0.001* 0.36 V̇O2peak/BSA*β 
(adjusted R2 = 
0.55) 
 
   
 Age (1, 46) = 2.979 0.091  
 PHV (1, 46) = 3.554 0.066  
 80  
 BMI (1, 46) = 1.839 0.182  
 FEV1 (1, 46) = 22.322 < 0.001*  
 Sex (1, 46) = 23.375 < 0.001* 0.34 V̇O2peak/Stature*β 
(adjusted R2 = 
0.52) 
 
   
 Age (1, 46) = 1.971 0.167  
 PHV (1, 46) = 4.272 0.044*  
 BMI (1, 46) = 1.831 0.183  
 FEV1 (1, 46) = 20.218 < 0.001*  
 Sex (1, 46) = 17.327 < 0.001* 0.27 
F values reported as (degrees of freedom) = F value. Alpha level set to 0.05, 
significant results are highlighted in bold and by *. h%& ; partial eta squared. V̇O2peak; 
peak oxygen uptake. V̇O2peak/BM*β; maximal oxygen uptake scaled to body mass 
and raised to the exponent 0.82. V̇O2peak/BSA*β; maximal oxygen uptake scaled 
to body surface area and raised to the exponent 1.29. V̇O2peak/Stature*β; maximal 
oxygen uptake scaled to stature and raised to the exponent 2.42. PHV; peak 
height velocity. BMI; body mass index. FEV1; forced expiratory volume in 1 s. 
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Figure 4.4. Adjusted means and ranges for absolute and scaled VO2peak 
parameters in males and females. Significant differences highlighted with an *.   
* 
* 
* 
* 
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5. Discussion 
 
The key aim of this thesis was to identify sex differences in CPET parameters in 
young people with CF. To address this aim, four key findings were identified: (1) 
There are no sex differences in V̇O2peak and other CPET parameters in relation to 
disease status defined by FEV1%predicted (tertiles); (2) Age and sex interacted to 
significantly explain differences in RCP (% V̇O2peak). No significant interaction 
effects were noted for any other CPET outcomes; (3) A novelty of this study 
showed that allometry appropriately removed the influence of body size in all 
parameters (BM, BSA and stature). When allometrically scaled for BM, BSA and 
stature, females had a lower V̇O2peak than their male counterparts; (4) After 
adjusting for various co-variates (lung function, nutritional and maturational 
status) sex differences still remained in absolute V̇O2peak, V̇O2peak/BM* β, V̇O2peak/BSA* β and V̇O2peak/Stature*β, but there was still ~50 % variance left 
unexplained. 
5.1 Sex differences in exercise parameters  
The findings in this thesis are consistent with previous literature in healthy 
children reporting females to have a ~0.3 L·min-1 lower exercise capacity than 
their male counterparts (Armstrong et al., 1997). However, the cause of such a 
difference is still under debate. When scaled using allometry and controlled for 
co-variates (FEV1, BMI, PHV and age), V̇O2peak was significantly affected by sex 
(females elicited lower values) indicating there may be mechanistic differences 
between males and females with CF. Klijin et al., (2003) proposed FFM to better 
adjust for body size in children with CF, explaining up to 9 % further variance than 
other body size variables, (such as BM, BSA and stature which were used in the 
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present study) due to the effect that CF has on muscle development (Boas et al., 
1996). Despite this, allometrically scaled BM, BSA and stature appropriately 
removed the influence of body size in the present analysis (Fig. 3.3). Klijin et al., 
(2003) did not consider the influence of maturation or age, reporting 47% of 
variance in exercise capacity was due to FEV1 and FFM. Wirth and colleagues 
(1978) reported V̇O2peak to be higher in healthy boys than girls and increase with 
maturity, however the increase and sex difference was likely due to the influence 
of body size as sex differences in V̇O2peak were non-significant when related to 
body mass. In the present analysis PHV was used to account for maturity status 
as the thesis population included paediatric participants. Although, PHV may not 
be a valid measure as calculations were established in healthy children and may 
not transfer in CF populations due to the complications with nutrition and stunted 
growth that some people with CF experience (Hankard et al., 2002). 
Unfortunately, commonly reported markers of sexual maturity such as Tanner 
stages, were not available to complement the estimate of PHV. No differences 
between males and females were noted in Smax verification, secondary criteria 
(HRpeak and RERpeak) and breathing frequency, suggesting females and males 
were working equally intensively. Therefore, it is very unlikely that V̇O2peak is lower 
in females due to a lack of effort or motivation in the present analysis. Similar 
conclusions have been previously reported on the cycle ergometer and treadmill 
in healthy children (Welsman et al., 1997). 
Armstrong (2006) provided reference values for peak V̇O2 in boys and girls, 48-
50 mL·kg-1·min-1 and 35-45 mL·kg-1·min-1, respectively, which was higher on 
average by ~35 % than the mean in this population (33 ml·kg-1·min-1 and 25 ml·kg-
1·min-1 for boys and girls respectively). Additionally, Adegboye et al., (2011) 
recommended that for metabolic health in non-diseased 15 year old boys and 
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girls, a minimum peak V̇O2 of 46 mL·kg-1·min-1 and 33 mL·kg-1·min-1 should be 
obtained, respectively.  When Bongers’ reference equations for healthy children 
were utilised (Bongers et al., 2014b; Appendix C), males and females with CF in 
the present study had 17.8 % and 34.6 % lower V̇O2peak (respectively) than they 
would if healthy. Therefore, the population in the present analyses were less fit 
than their healthy counterparts based on predictive equations. However, 
Bongers’ reference equations were not developed in the CF population, and were 
identified from a Dutch population which may not transfer to a British population. 
Compared to CF populations, the participants in this analysis had on average a 
0.21 L·min-1 and 6.48 ml·kg-1·min-1 lower V̇O2peak than participants in a study by 
Saynor et al., (2014). Although, Saynor and colleagues (2014) identified V̇O2peak 
in only 10 children with CF and a mean age ~4.3 y younger than the present 
analysis, the age difference might explain the small discrepancy in V̇O2peak 
despite equivalent protocols being used and participants from the same region of 
the UK. However, the present analysis appears to show an increase in V̇O2peak 
with age, therefore the lower exercise capacity despite a higher average age 
could suggest a difference in disease severity between the two populations. 
Furthermore, participation in the study by Saynor et al., (2014) was voluntary, 
offering a potential selection bias towards milder disease severity and aerobically 
fitter CF cohort. It is difficult to identify exactly where this population fits in terms 
of relative fitness due to the age range of the present population spanning from 
childhood, adolescence into early adulthood. However, when comparing FEV1 
tertiles (Fig. 4.3) the lowest tertile includes a range of 29.59 to 77.33 % predicted 
FEV1. This suggests that in terms of disease severity, this population was 
relatively fit and healthy as > 70 % is considered a mild disease status. Significant 
differences seen between males and females in terms of V̇O2peak may only be 
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identifiable within the patients with more mild to moderate disease severity as 
they are most similar to a healthy population than those with severe CF. There is 
limited research investigating the severe CF population, but it is possible that the 
sex differences in V̇O2peak may not be as noticeable in severe CF participants, as 
in mild to moderate CF.  
In this population, females with CF have a significantly greater percentage 
difference between their absolute V̇O2peak and absolute V̇O2peak reference values 
from Bongers et al., (2014b) than males (-34.6 % and -17.8 % difference 
respectively). This exacerbates the already significantly lower exercise capacity 
in healthy females experienced. Therefore, the implications of a lower exercise 
capacity in healthy females is widened further by CF in females.  Due to the 
relatively healthy CF population, as defined by FEV1%predicted, this additional 
separation between males and females in terms of exercise capacity may be 
increased in a severe CF population. However, it is important to note that the 
Bongers reference values are based on age and sex alone, neglecting other 
possible factors such as body size variables, which may account for the greater 
percentage difference V̇O2peak experienced in females.  
In a cross-sectional study involving 83 participants (47 males) it was reported that 
those with CF and a glucose intolerance had a lower exercise capacity than those 
without a glucose intolerance (Foster et al., 2018). In the present analysis twice 
as many females had CFRDM than males, suggesting a possible explanation for 
the lower exercise capacities seen in females. However, it may be that those 
people with CFRDM, or a glucose intolerance, have a reduction in PA due to the 
demands of managing CFRDM, and therefore a reduction in exercise capacity 
rather than a direct causal relationship.  
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Although V̇O2peak was significantly lower in females, V̇O2 gain (males 7.2 ± 1.8 
mL∙W-1∙min-1 and females 6.8 ± 1.7 mL∙W-1∙min-1) was not significantly different 
between sexes. It is documented that CF patients have impaired oxygen uptake 
kinetics compared to their healthy counterparts, with average functional gain of 
CF patients equalling 8 ± 3 mL·W-1·min-1 (Fielding et al., 2015), similar to the 
whole group average V̇O2 gain in the present analysis (7 ± 2 mL·W-1·min-1). 
Therefore, despite no differences between sexes, this population may have 
experienced impaired oxygen uptake kinetics compared to the healthy 
population. However, the CF population in the study by Fielding et al., (2015) did 
have a lower gain than the healthy controls, which alongside a delayed V̇O2 
response, was attributed to impaired oxygen transport and utilisation in the 
muscles.  
Peak power, absolute and relative to body mass, were significantly lower (~68 W 
and ~1 W∙kg-1 respectively) in females than males. This finding shows that, 
although only a small difference when presented relative to body mass, females 
are less effective at producing power, however FFM or MM would be a more 
appropriate measure to identify whether this is a purely muscle compositional 
constraint. It is well documented that adult males and females have different body 
compositions with males eliciting higher proportions of muscle mass than females 
(Schorr et al., 2018; Bredella, 2017; Abe et al., 2003), however, this is heavily 
dependent on maturation when researching children (Loomba-Albrecht and 
Styne, 2009). It may be that females have less FFM/ MM than males and 
therefore cannot produce the same power per unit of body size. There have been 
reports of structural differences in muscles types between sexes in mice (Eason 
et al., 1985) and healthy human populations (Staron et al., 2000) with the 
expression of type II fibres of the vastus lateralis muscle being more prominent 
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in males than females (Haizlip et al., 2015; Staron et al., 2000). Fast twitch 
muscle fibres in the vastus lateralis (quadriceps), may be particularly important 
towards the latter stages of incremental maximal testing on cycle ergometers, 
where the participant is working anaerobically with greater load. Further studies 
have shown some differences in contractile properties between healthy men and 
women (Gandevia 2001). However, many of these studies have been isolated to 
single muscles, with different muscles used between studies, making it difficult to 
generalize findings to the entire body. Furthermore, Blimkie and Sale (1998) 
described no sex differences in muscular force in healthy cohorts once the 
influence of muscle cross sectional area is considered. The CF literature does 
not report whether there are sex differences in skeletal muscle properties, likely 
due to research aiming to identify differences between CF and healthy controls. 
People with CF have been reported to have a reduced oxidative work 
performance (de Meer et al., 1995), similar contractility, fatigability (Gruet et al., 
2016) and lower maximal torque in the vastus lateralis and medialis than healthy 
controls, this was reported to be due to less developed musculature rather than 
a direct result of the CFTR defect (Stein et al., 2016). It could be that males and 
females with CF have differences in muscular properties due to differences in sex 
rather than the impact of CF. 
Submaximal parameters such as GET absolute and relative (ml·kg-1·min-1) were 
significantly lower (~0.4 L∙min-1 and ~5 mL∙kg-1∙min-1 respectively) in females than 
males. However, these parameters are closely linked to absolute value of V̇O2peak 
so may be biased, as females have a lower V̇O2peak. Conversely, GET as a 
percent of V̇O2peak was not significantly different between sexes, this parameter 
removes the influence of absolute V̇O2peak attainment.  
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Females have a significantly lower peak V̇E than males accompanied by no 
difference in breathing frequency, suggesting females are unable to inhale in as 
much air as males or do not inhale as deeply to compensate. This could explain 
part of the lower peak V̇O2 in females, however this again may simply be due to 
the influence of body and lung size. In healthy children, stature is reported to be 
the main predictor of vital capacity (Bhatti et al., 2014). Females in the present 
analysis were significantly ~10 cm (p = 0.027) smaller in stature and experienced 
~0.5 L lower tidal volume, supporting the idea that lung size could be the reason 
for a lower V̇Epeak in females.  
Previous literature has reported no significant differences in V̇E/V̇CO2 slope 
between CF and healthy controls (age, sex and anthropometrically matched; 
Bongers et al., 2014a) however V̇E/V̇CO2 slope values in the present analysis 
were ~5-7 units higher than the CF group in the study by Bongers et al., (2014a). 
This suggests the group in the present analysis may have greater dead space 
fraction and/ or lower partial pressure of CO2 as seen in healthy subjects with 
greater V̇E/V̇CO2 slope values (Sun et al., 2002). There were no significant 
differences between males and females in terms of V̇E/V̇O2 (absolute and slope) 
and V̇E/V̇CO2 (absolute and slope) despite ventilatory equivalents of O2 and CO2 
significantly predicting mortality in children with CF (Hulzebos et al, 2014) and 
females having a higher mortality (Dodge et al., 2007; Liou et al., 2001; Corey et 
al., 1997; Rosenfeld et al., 1997) which factors such as nutrition or pulmonary 
function cannot explain (FitzSimmonds, 1993). Furthermore, literature in healthy 
adults has reported significant sex differences in V̇E/V̇CO2 during an incremental 
cycle test to exhaustion (Neder et al., 2001). The results in this thesis are 
consistent with previous findings in healthy children (Armstrong et al., 1997). In 
addition, Tucker et al., (2019) reported no sex differences in V̇E/V̇O2 (peak) and 
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V̇E/V̇CO2 (peak and slope) in people with CF at baseline, but females exhibited a 
greater decline in ventilatory equivalents (p = 0.001, p = 0.002 and p = 0.016 
respectively) than males over ~3 years, despite no change in V̇O2peak. The 
authors attributed this to reduced CO2 production and/ or reduced sensitivity to 
arterial CO2 in females with CF. Furthermore, Tucker and colleagues (2019) 
suggested that deteriorations in ventilatory dynamics may precede the decline in 
exercise capacity and therefore be a more sensitive prognostic tool than V̇O2peak 
for monitoring mortality between sexes. However, in the above study by Tucker 
et al., (2019), no significant differences were reported in V̇O2peak absolute or 
relative to body mass which are inconsistent with the present findings. This may 
be due to; stricter exclusion criteria, a smaller sample size (20 compared to 52), 
raw data averaged into 30 s (rather than 10 s averages) and no Smax verification 
in the Tucker study compared to the present analysis. 
Females demonstrated significantly lower values for oxygen pulse (V̇O2/ HR) in 
the present analysis (~4 mL∙min-1), which is likely due to the higher V̇O2peak in 
males combined with no sex differences in HR. This implies less oxygen is taken 
up with each cardiac contraction in females, although females may have 
significantly smaller ventricles than males causing this phenomenon. 
Comparisons between the sexes were not significantly different in terms of BM, 
BSA or BMI indicating males and females may have similar heart sizes by 
extrapolation. However, previous studies in participants without heart disease 
reported stature to significantly affect heart size (Pfaffenberger et al., 2013). In 
the present study, females were significantly smaller than males supporting the 
idea that they had smaller hearts. In patients with coronary heart disease, oxygen 
pulse has been reported to add no additional information than V̇O2peak in relation 
to fitness or prognosis (Laukkanen et al., 2006), suggesting perhaps this 
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parameter is negligible. However, previous literature in CF has identified 
ventricular dysfunction both in relation to (Giacchi et al., 2015; Ionescu et al., 
2001) and independent of (Sellers et al., 2013) disease status. Furthermore, in a 
variety of different patient populations, sex differences are apparent in 
parameters of ventricular dysfunction (Ferreira et al., 2015; Coutinho et al., 2013; 
Hameedullah et al., 2012), therefore females with CF may have greater 
ventricular dysfunction compared to males.  
V̇O2max was verified if V̇O2peak determined from the Smax was < 9 % outside of the 
ramp V̇O2peak as reported by Saynor et al., (2013a). In the present population only 
66 % of the 47 participants that underwent the Smax were verified to have attained 
true V̇O2max, compared to ~90 % in a healthy population (Saynor et al., 2013a). 
However, the CPET data was taken as the first CPET recorded at the NHS Trust 
Hospital, some participants may have never before performed an exercise test or 
been on an exercise bike and others may have moved from a previous hospital 
where they were subject to CPETs. Offering the possibility that there may have 
been a learning effect to the protocol between the ramp and Smax bout, enabling 
greater effort in the Smax bout. Average peak HR, a surrogate measure of effort, 
increased from 177 bpm to 179 bpm from ramp to Smax bout suggesting this 
learning effect may have been minimal. Additionally, Saynor et al., (2013b) 
reported no learning effect of maximal incremental cycle tests. V̇O2max was 
reproducible over 8 hours and 4-6 weeks in children with cystic fibrosis. 
Sub maximal measures such as GET (% V̇O2peak), V̇E/V̇CO2 slope and V̇E/V̇O2 
slope were not different between males and females suggesting no difference at 
a submaximal level, however differences at maximal level (V̇O2peak) are noted. 
This is similar to findings in healthy populations that suggest multiple similarities 
between males and females at submaximal intensities (Deschenes et al., 2006) 
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and higher stroke volume in males being attributable to greater heart sizes 
(Wilmore et al., 2001; Wiebe et al., 1998). Some studies have noted greater HR 
of females during submaximal exercise (Seebauer et al., 2003; Wilmore et al., 
2001), which is postulated to compensate for a lower stroke volume. Furthermore, 
Deschenes and colleagues (2001) reported healthy males to have higher (p = 
0.04) utilisation of CHO sources than healthy females at prolonged submaximal 
intensities, due to higher RER values in males. However, RER was not 
significantly different between males and females at any point (Smax, ramp or peak V̇O2) in the present analyses, suggesting similar efficiency of utilising fats and 
CHO between the sexes at maximal exercise. These results support findings at 
maximal exercise in healthy trained athletes (Goedecke et al., 2000), however 
both the study by Goedecke et al., (2000) and the present study did not account 
for menstrual cycle in females, which may alter substrate utilisation due to 
hormonal fluctuations (Devries et al., 2006; Zderic et al., 1985). Although, the 
above studies used very different sample groups than the present thesis.  
Absence of interaction effects was noted for sex in relation to FEV1%predicted 
(tertiles) and all but one parameter (RCP % V̇O2peak) for sex in relation to age 
(tertiles). This suggests that the influence of sex on cardiopulmonary exercise 
variables is not reliant on age or disease status as defined by lung function. From 
both of these models, sex can statistically account for variance in all V̇O2peak 
parameters. These results complement those of the t-test results, however there 
are exceptions and differences in p values between the two different two-way 
ANOVA models. Although the interaction effect is non-significant, it is still 
accounted for in the model, potentially making the main effects noted subtly 
different than if run without the interaction. Whilst it can be suggested that sex 
influences variance in a number of CPET outcomes (V̇O2peak absolute and 
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relative, peak power [W and W∙kg-1], TTE, V̇CO2peak, RCP % V̇O2peak, GET [L∙min-
1 and ml∙kg-1∙min-1], V̇Epeak, tidal volume, BF and oxygen pulse) not all of these 
outcomes have statistically significant group means between males and females 
(see Table 4.3. for significant t-test results). 
5.2 Influence of lung function on exercise parameters 
Irrespective of whether male or female, FEV1%predicted tertiles significantly 
explained variance in many CPET parameters including V̇O2peak absolute and 
scaled using allometry. The relationship between lung function and exercise 
capacity has been previously noted by Pastre et al., (2014), who stated that an 
impaired V̇O2peak was more pronounced in participants with a low FEV1. Tucker 
et al., (2017) reported preservation or improved lung function following an acute 
bout of maximal exercise and this improvement was related to peak work rate 
and V̇Epeak. Although the present analyses did not include follow up tests of lung 
function, no significant relationship was noted between lung function and V̇Epeak 
or peak power, which is in contrast to the above study by Tucker and colleagues.  
A strong positive correlation between FEV1 and GET was observed (r = 0.71), 
associating the greater lung function the greater submaximal performance. It is 
difficult to infer a direction of causality of the correlation due to the cyclical effect 
of one parameter on the other. A person may not be conditioned, resulting in a 
lower GET (Ghosh, 2004), and therefore lung function declines. We know 
maximal exercise training can improve respiratory function (Tucker et al., 2017). 
This improvement in respiratory function is attributed to improvements in 
voluntary and involuntary muscle strength and efficiency of muscles utilising 
oxygen (Hulke et al., 2012). Similarly, the correlation between relative peak power 
and lung function could be due to the patient doing more exercise and therefore 
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have greater MM or anaerobic power as a result of a training effect (Radtke et 
al., 2017), which in turn aids improvement in lung function or a greater lung 
function facilitates the ability to exercise and improve peak power. However, it 
can be inferred due to the moderate correlations (r = 0.5), that higher fitness 
levels are related to better lung health in CF (and vice versa), synonymous with 
previous literature (the author failed to report the correlation coefficient; Pianosi 
et al., 2005b).  
5.3 Influence of age on exercise parameters 
The median age of patients in the present analysis was 17 y, 3 years younger 
than the UK CF population (20 y) (UK Cystic Fibrosis Trust, 2017). Despite 
median age being similar, this analysis had an upper age range of 25 y therefore 
we cannot infer that this sample is representative of the whole CF population.  
Pearson’s correlation analysis revealed a weak positive correlation between age 
and V̇Epeak (Fig. 4.2). Upon visual inspection of the data points in the correlation, 
it can be noted that V̇Epeak appears to increase with age up to a point (~17 y) 
before then declining. When a bi lateral correlation approach was utilised, a 
strong positive relationship was noted up to the age of 17 y and a moderate 
negative correlation from 17 – 25 y. This observation can lead to the conclusion 
that simple linear regression is not suitable to identify the correlation in this 
example, and perhaps a more comprehensive quadratic regression approach or 
partial correlation may be more appropriate. Previous literature has not 
addressed the relationship between age and minute ventilation in CF. 
Longitudinal analyses in healthy children have noted increases in V̇Epeak 
throughout childhood (Rowland and Cunningham, 1997). It is likely that the 
increase noted throughout childhood is related to the increases in body size. In 
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contrast to the present observation, in healthy populations it has been noted that 
there are greater ventilatory responses during exercise in elderly participants 
compared to young (Prioux et al., 2000; Brischetto et al., 1984), which suggests 
ventilatory responses in CF are altered with age compared to healthy populations. 
Additionally, age related declines in ventilatory parameters, throughout 
childhood, have been reported in CF populations (Pianosi and Wolstein, 1996). 
The novel bi-lateral correlation between V̇Epeak and age noted in the present 
analyses warrants further investigation into the causality between the two 
variables in young people with CF. 
Differences in V̇O2peak (L∙min1), V̇O2peak/Stature*β, peak power (W), TTE (s), V̇CO2peak (L∙min1), RCP (% V̇O2peak), GET (L∙min1), V̇Epeak (L∙min1), #̇E/#̇O2 (L∙min-
1), tidal volume (L) and RERpeak could be attributable to age as defined by tertiles. 
It is interesting to note that V̇O2peak scaled to stature was significantly different 
between age tertiles, however V̇O2peak scaled to BM or BSA was not. This is 
perhaps because in the present analysis stature is treated as a linear dimension 
and does not consider the change in volume with growth. Absolute V̇O2peak was 
observed to increase between lowest and middle tertiles then decrease between 
middle and highest age tertiles, confirming the well documented findings in 
previous literature that exercise capacity declines with age in adults with CF 
(Weert-van Leeuwen et al., 2012).  
5.4 Applications and future research 
The overriding observation from the results in the present analysis is that females 
with CF have a reduced exercise capacity than their male counterparts 
irrespective of the scaling method, body size variable used or clinical co variates. 
Therefore, females with CF may require a more tailored programme of exercise 
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than males to aid in managing the disease, with all programmes scaled to a 
parameter of capacity such as V̇O2peak. Future research should focus on 
identifying effective programs and individualising for males and females to 
enhance exercise capacity. Furthermore, literature has shown that children and 
adolescents with CF engage in less rigorous PA than their healthy counterparts, 
despite having healthy lung function (Nixon et al., 2001); and females with CF 
engaged in less PA in general compared to males with CF (Schneiderman-
Walker et al., 2005). Therefore, the level of habitual PA should be considered as 
it is possible that females have a lower exercise capacity due to less participation 
in PA, rather than a direct result of a sex effect.   
Many differences between sexes in CPET parameters are removed by 
accounting for body size or could be influenced by body size. In the clinical 
environment it would be more appropriate to compare group’s parameters when 
scaled for body size variables. When age, lung function, body size and maturation 
are all taken into account, females still had a lower exercise capacity suggesting 
the possibility that differences in muscle size, efficiency or cellular variances 
could be the cause. Future research should aim to allometrically scale all exercise 
parameters to aid in comparisons and perhaps use of FFM or MM may be more 
appropriate than the body size variables used in the present analysis. It is likely 
that controlling for FFM or MM will explain additional variance in V̇O2peak but still 
leaving some variance unexplained. Previous research has identified that mild to 
moderate CF participants experience changes in aerobic metabolism compared 
to healthy individuals that was intensity dependent (Saynor et al., 2016). 
Therefore, these observations propose muscle oxygen extraction and utilisation 
is impaired in mild to moderate CF and future research should look to identify 
whether muscle oxygen utilisation and extraction are key to the differences in 
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maximal exercise capacity between the sexes in children with CF. Perhaps clinics 
around the UK should implement dual-energy X-ray absorptiometry scans, for 
measures of FFM or MM, into their annual review alongside basic measures of 
body size. This could help to provide a greater insight into body composition and 
enable more in-depth analyses of CPET results in the future. Although the small 
radiation risk, equivalent to less than two days exposure to natural background 
radiation (NHS, 2019), should be considered at an individualised level prior to 
any scan.   
Additional correlational analyses may be required to further our understanding of 
relationships between clinical variables and CPET parameters. FEV1 is correlated 
strongly to GET and relative peak power, but it may be similar relationships can 
be used to predict submaximal and maximal measures in clinics that cannot 
perform CPETs. 
There is the scope that these results can be used as reference data for the south 
west region of the UK and specifically the RD&E hospital for ages 8 – 25 y. 
Furthermore, the systems in place to record data could be improved. At the 
present, clinical data is stored separately to CPET files and some CPET 
measures are in paper form making it difficult to combine all parameters for an 
overview of the patient. If the system is upgraded then it may help healthcare 
professionals e.g., physiotherapists and technicians see the ‘whole picture’ to 
better aid in the care of patients. 
5.5 Limitations 
The main limitation to this thesis is the lack of other body compositional measures 
such as FFM and MM that a prospective study could have been collected. With 
the addition of these parameters, the influence of body size could have been 
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entirely ruled out, leaving other qualitative parameters to explain any remaining 
variances. However, this retrospective analysis has made use of existing data 
from the hospital, which may not have been comprehensively analysed otherwise 
due to the busy schedules of clinical staff.  
CPETs were completed in the clinical environment rather than the laboratory, 
therefore were subject to practical constraints such as appointment times, 
different experimenters, faulty equipment and annual review occurring on 
separate days to the exercise test. This meant in some cases the Smax was not 
completed or HR did not register, which may have been resolved if in the 
controlled scientific laboratory environment. Furthermore, CPETs used in this 
thesis were taken as the first CPET completed at the RD&E hospital, which may 
not have been the first CPET the patient had ever done, potentially meaning there 
may have been the issue of a learning effect between ramp and Smax or between 
patients. Although rigorous statistical analyses produced similar findings to 
previous literature, which confirms this may not have had such an impact on the 
results and conclusions.  
Another limitation in the present analysis was that FEV1 and other clinical 
parameters were not taken in conjunction with the exercise test due to 
practicalities of working within a clinical environment. However, this effect may 
be limited as studies have shown that the relationship between FEV1%predicted and V̇O2peak is not perfect, 50 % variance in V̇O2max explained by FEV1%predicted and r = 
0.71 (Pastre et al., 2014). Hence, the small variance in time between CPET and 
annual review may be negligible. 
Additionally, a control group of healthy males and females would have provided 
further insight into whether the sex differences noted in the present analyses were 
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due to sex or an interaction of sex and CF. The differences observed here may 
be the same noted in healthy females and therefore not any different when in 
terms of CF. Furthermore, it is possible that this sample group is biased towards 
the fitter patients as taking part in the CPET is optional and often those with 
contraindications or very severe CF were not able to undertake the test. 
5.6 Conclusion  
In summary, this thesis demonstrates that in a young CF population, V̇O2peak is 
significantly reduced in females compared to males. These observations were 
persistent throughout scaling, irrespective of the method or body size variable 
used, and after controlling for age, maturity and nutritional status. Previous 
literature has not yet comprehensively utilised these methods to determine sex 
differences in exercise capacity, therefore this thesis allows further interpretation 
of sex differences in aerobic fitness for CF populations.  
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APPENDIX C 
Bongers Reference Values 
Age #̇O2peak Reference Value % Difference 
Boys 
17.65 2.54 3.43 26 
16.35 1.44 3.12 54 
15.92 2.73 3.02 9 
11.05 1.68 1.94 13 
9.54 1.25 1.64 24 
17.21 2.72 3.33 18 
17.50 3.27 3.40 4 
16.71 3.59 3.20 -12 
9.30 1.08 1.59 32 
17.74 2.20 3.46 36 
12.07 1.24 2.15 42 
10.92 1.30 1.91 32 
17.05 3.08 3.29 6 
13.22 2.16 2.40 10 
8.82 1.19 1.50 21 
13.49 2.25 2.46 9 
13.75 1.46 2.52 42 
13.97 3.29 2.57 -28 
16.04 3.06 3.04 -1 
Girls 
10.23 1.03 1.53 33 
12.15 1.14 1.86 39 
16.90 1.90 2.59 27 
11.86 1.13 1.81 38 
15.24 1.11 2.34 53 
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9.82 0.94 1.46 36 
16.56 1.83 2.54 28 
13.90 1.78 2.14 17 
13.12 1.37 2.01 32 
11.87 0.97 1.81 46 
12.51 1.26 1.92 34 
12.07 1.22 1.84 34 
 
